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Tuberculosis (TB) is a significant global health problem and the development of new TB 
vaccines is one strategy proposed to address this scourge. Adolescents are a potential 
target group for new TB vaccines. Limited data are available in the scientific literature 
on the epidemiology of TB in adolescents. This thesis aimed to add substantial data on 
adolescent TB epidemiology through a cohort study of TB infection and disease in 
adolescents in a high burden setting. Such data will support clinical trials of new TB 
vaccines in adolescents but the knowledge gained will also be of value for TB Control 
Programmes. 
Methods 
Adolescents aged 12-18 years were recruited from 11 high schools in the rural town of 
Worcester and surrounding areas of the Western Cape Province of South Africa. They 
were screened at baseline for latent TB infection using both the tuberculin skin test 
(TST) and an interferon gamma release assay, the QuantiFERON® TB Gold (in-tube) 
assay (QFT). They were also screened for TB disease using an algorithm composed of a 
set of screening tests.   They were followed up for at least two years for incident TB and 
the predictive value of the baseline TST and QFT for incident TB disease was compared. 
Demographic, socio-economic and clinical predictive factors for latent TB infection 
prevalence at enrolment and for incident TB disease during follow up were determined. 















adolescents from these schools was also conducted. Both studies had ethics approval. 
Standard scientific statistical techniques were used to analyse the data. 
Results  
Fifty eight percent (6363) of the target population of 10,492 adolescents were recruited 
into the main cohort study. A prevalence of latent TB infection amongst the study 
participants at enrolment of 55% (TST) and 51% (QFT) was found. Predictive factors for 
latent infection were: being of black or mixed race origin compared to being of white or 
indian origin, older age (>15 years), previous household TB contact, low parental income 
and low education status of the parents.  The TST and QFT were f und to have good 
agreement (% agreement 84.8%, kappa [κ] = 0.70, 95%CI 0.68–0.71) in contrast to 
certain studies in other settings. A baseline prevalence of TB disease of 3/1000 was 
found in adolescents. While the TST and QFT were sensitive predictors of the presence 
of TB disease, none of the screening tests evaluated (TB related symptoms, recent 
household contact, TST or QFT) had high positive predictive values (all less than 2%) 
making these tests impractical for routine use. Given the imperative for screening in TB 
vaccine trials, these data are important for deciding on choice of screening tests in a 
clinical trial setting.  Both the TST and QFT were found to be predictive of the onset of 
TB and were equally predictive.   An incidence of bacteriologically confirmed active TB of 
0.45/100 (95% confidence interval 0.29-0.72) person years (pyrs) was found in this 
cohort. Using different definitions of active TB, the rate varied from 0.31-0.59/ 100 pyrs.  
Risk factors gleaned at baseline that were predictive of the onset of TB disease were: 















unknown, evidence of latent infection (positive TST or QFT) and absence of a BCG scar.   
Knowledge of TB was fair amongst adolescents but willingness to participate in TB 
vaccine trials varied depending on the procedures involved. 
Limitations 
Important limitations were as follows. The data presented are likely to underestimate 
the true prevalence and incidence of TB amongst adolescents in general since 
adolescents not at school are likely to have higher rates of TB than those attending 
school. On the other hand TB rates amongst those recruited are likely to have been 
higher than those not agreeing to participate since participation rates were higher in 
poorer schools than in more affluent schools. Chest radiographs as a screening tool for 
TB could not be evaluated because this method of screening was excluded for logistical 
reasons. The number of TB cases is likely to have been underestimated since smear 
screening was the main method of case detection and smear negative culture positive 
TB cases would have been missed. 
Application of results 
 A range of data was obtained through these analyses which will be very useful for 
planning TB vaccine trials in adolescents and also for TB Control Programmes. Since data 
were collected in a high TB burden setting, the findings are mainly generalisable to such 
settings rather than low burden settings.  Nevertheless, efficacy trials of new TB 
vaccines are likely to be carried out in high TB burden settings making these results 
highly relevant to TB vaccine efficacy trial planning.  Policy with respect to the use of 















new diagnostic modality. Knowledge of the baseline prevalence of TB disease and the 
utility of different screening tools amongst healthy adolescents would help the design 
and costing of screening approaches to be used in TB vaccine clinical trials which include 
adolescents. The data on the prevalence of latent TB infection will assist with the 
selection of TB vaccine candidates for this target group will be of value given that 
certain vaccines are designed to target those with latent infection. These data will also 
support planning where latent TB infection is an exclusion criterion such as in safety 
trials. TB incidence rates can be used to plan samples sizes for efficacy trials. The 
comparison of the TST and QFT with respect to prevalence of latent TB infection and 
predictive value for TB disease provide evidence for policies on the use of these tools in 
clinical trials and for TB Control Programmes in high burden settings. The fact that these 
measures showed good agreement and were equally predictive of the onset of TB 
disease, suggest that the QFT need not replace the TST in current routine practice. 
However, the two tests may be used interchangeably to equal effect.  The knowledge 
and attitudes of adolescents towards participation in TB vaccine trials provides some 
guidance with respect to what to expect when approaching this group for recruitment 
purposes. 
In summary, the prevalence of latent TB infection, the prevalence and incidence of TB 
disease and predictive factors for latent infection and disease as well as the knowledge 
and attitudes of adolescents towards participating in TB vaccine trials are described in 
this thesis. The application of these results to TB vaccines trials and potential value in TB 
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Glossary of abbreviations and terms 
Adolescent   – any child from 12 to 18 years of age. 
Active TB  – the presence of active disease processes in the body usually 
associated with the presence of Mycobacterium tuberculosis or 
typical histological changes. 
BCG    - Bacillus Calmette Guérin 
Boost vaccine - a vaccine given in addition to another vaccine for the same 
disease but usually at a later time point. 
HIV    - Human Immunodeficiency Virus 
IGRA    - interferon gamma release assay 
Latent TB infection  – a state whereby Mycobacterium tuberculosis is present in the 
body in a contained way without the host experiencing any 
feelings of ill health. Usually measured through the presence of a 
positive TST or IGRA. 
PPD    - Purified Protein Derivative (of tuberculin) 
QFT  - QuantiFERON® TB Gold (in-tube) assay (Cellestis, Victoria, 
Australia) 
TB    - tuberculosis. 
TB prevalence  – the number of active TB cases at a point in time as a proportion 
of total number at risk. 
TB incidence  – number of new cases of active TB occurring over a defined 
period 
TST    - Tuberculin Skin Test 















Note on included publications: 
Please note that the final accepted version of the manuscript of each paper is included in this 
thesis according to the formatting style of the journal concerned including the references. The 
referencing and references in all other sections are according to the Vancouver method. The 
tables and figures for the papers are shown after the references in the applicable chapter. For 
the other sections, figures and tables are shown in the text. 
Note on references 
Please note that each chapter has its own reference list. 
Note on TST cut-offs used 
A number of cut-offs for the tuberculin skin test (TST) are used in this thesis. During study 
design, 10 mm was used as a cut-off as a level above which an investigation for TB was 
performed since this was the cut-off commonly used in clinical practice and in the South African 
National TB Control Programme guidelines (see 2009 edition). A reviewer of the paper in 
reflected in chapter 3, however, argued that a cut-off of 5 mm be used for analysis as this made 
more sense given the distribution of TST indurations. Thus reference to both cut-offs are found 
throughout the thesis. In addition, the 15 mm cut-off was used for certain analyses as this is 
regarded by many in the literature as the most specific cut-off indicating latent TB infection 
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Chapter 1: Introduction 
Tuberculosis (TB) remains one of the major health challenges in the world today.  The World 
Health Organisation (WHO) has estimated that 8.7 million people were diagnosed with TB and 
1.4 million died of TB in 2011 (1).  A global alliance of TB stakeholders, the STOP TB Partnership, 
has set out a strategy for combating TB globally (2). Included are strategies for better TB drugs, 
improved diagnostics and more effective vaccines.  The current vaccine against TB, Bacillus 
Calmette Guérin (BCG)(currently administered at birth in mainly developing countries) is known 
to be at least partially effective against disseminated forms of TB in young children but has 
variable efficacy against pulmonary forms of TB (3, 4). Since the 1990s, there has been a 
groundswell of effort to develop new TB vaccines with 12 vaccines currently being actively 
tested in clinical trials (5). Among these new TB vaccines, some are  classified as pre (latent TB) 
infection, others as post (latent TB) infection and still others as therapeutic (6).  Review and 
modelling of interventions to tackle the TB epidemic show that new TB vaccines have a 
potentially powerful role in combating TB (7-9). Murray and Salomon of the Harvard School of 
Public Health developed an epidemiological model published in 1998 which showed that a new 
vaccine with 50% efficacy could lower TB incidence by 36 million and prevent 9 million deaths 
over a period of 32 years if introduced in 1998 (8).  Abu-Raddad et al. have shown  using a 
mathematical model that a combination of novel TB drugs, diagnostics and vaccines could 
reduce TB incidence by 71% (7). Dye and Williams in their review aver that a technology that 
could “remove or neutralize [TB] infection” such as a new TB vaccine “could radically alter the 
approach to TB Control”.  
Age curves of TB show peaks in numbers and incidence in young children and adults (10-12) 
















Figure 1: Age distribution of TB cases in Cape Town:  Department of Health, Provincial 
Government of the Western Cape Province, 2004 
 
Figure 2: Incidence rate by age (0-19 years) 
 




















All TB Incidence Rate by age for the Cape Metropole for July 2002 to June 2003 with 







































Given this distribution of TB cases, vaccine developers have focused on infancy and adolescence 
as age group targets for new TB vaccines. However, limited data are available on TB in 
adolescence. There was thus a keen interest in gathering more data on TB in adolescents so as 
to plan vaccine trials in this group. In addition, their potential for a pre-infection vaccine and 
their accessibility through schools as a vaccine target group were also areas requiring 
exploration.  Specific information of interest on adolescent TB for stakeholders in the TB vaccine 
field has been:  
 Incidence rates – to plan sample sizes for trials; 
 Prevalence of latent TB infection (LTBI) – given that some TB vaccines are designed as 
pre latent TB infection vaccines while others are specifically designed as post latent TB 
infection vaccines; 
 Morbidity and mortality, so that background severe adverse events could be 
anticipated;   
 Screening tools for TB so that active TB could be excluded at baseline and detected 
during follow up; and 
 Case-finding strategies and diagnostic algorithms for active TB. 
Study setting 
The South African TB Vaccine Initiative of the University of Cape Town, South Africa has an 
established research site in Worcester, about 110 kilometres from Cape Town. This area has a 
high reported all ages TB incidence rate based on routine data, of 1400/ 100 000 (13). The 
population of the Worcester and surrounding areas (Breede Valley Municipality) where the 
adolescent cohort study took place was estimated to be about 154 945 in 2010 (as provided 















mainstays of the local economy.  Based on the 2001 Census, only 26.6% of adults had 
completed a high school or higher level of education and 49.0% of employed persons earned 
R800 (~$90) or less per month. The ethnic composition of the population is mainly “coloured 
or mixed race” (66%), 20% “black” and 14% “white”. Roughly 52% of adults were employed, 
13% unemployed and 36% not economically active. 
Figure 3: Map of location of SATVI trial site in Worcester relative to Cape Town. 
 
A large trial comparing two methods of administering BCG was conducted at this site from 2001-
2006 which prepared it for testing new TB vaccines (14). Six of the twelve vaccines being tested 
globally have been or are being tested at this site.  It was in this context that a large adolescent 















Aims and Objectives 
The author of this thesis was employed by SATVI during this period and was responsible for the 
conduct of this cohort study. The data generated on adolescents in this study form the basis of 
this PhD. Prior to the start of the cohort study, new interferon gamma release assays were 
starting to be used to measure latent TB infection as an alternative to the tuberculin skin test 
(TST) (15). There was thus interest in the role such tests could play in the TB vaccine trial arena.  
This was incorporated into the adolescent study. 
While the main focus of the work was on relevance to TB vaccine trials, it was considered 
important to examine the application of the results obtained to TB care in general, to policies on 
diagnostic procedures and to the general health care of adolescents.  Since data collection was 
to take place in the high TB burden setting described above, th  results would be more 
applicable to other similar high TB burden contexts. 
The main aims of the thesis thus were: 1) to describe key aspects of the epidemiology of TB in 
adolescents which would support the conduct of TB vaccine efficacy trials in this group and 2) to 
examine the public health implications of the epidemiological findings for TB Control 
Programmes in high TB burden settings. The thesis thus set the following objectives which form 
the main chapters of this thesis: 
1. To determine the prevalence of and predictive factors for latent TB infection in 
adolescents. 
2. To determine the prevalence of TB disease in adolescence and the utility of various 
screening methods.  
















4. To compare the predictive value of the tuberculin skin test to that of an interferon 
gamma release assay in predicting TB disease onset. 
5. To determine the knowledge and attitudes of adolescents towards participating in TB 
vaccine trials. 
Ethics approval 
Two protocols approved by the Faculty of Health Sciences Human Research Ethics Committee of 
the University of Cape Town were the basis for the collection of the data for these objectives: 
1) A Knowledge, Attitudes and Beliefs Study of School-going Adolescents in the Worcester 
area with regard to TB Vaccine Research (UCT REC reference: 430/2004). 
2)  A Prospective Epidemiological Study of TB Disease and TB Infection in Adolescents in 
the Worcester and Surrounding Areas, Western Cape Province, South Africa (UCT REC 
ref: 045/2005). This study was known as the “Adolescent Cohort Study” and is referred 
to in some part of this thesis as such. A summary of the overall methods for this cohort 
study are set out in Appendix A and B since each chapter only describes the methods as 
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Chapter 2: Literature review 
Introduction 
Tuberculosis (TB) is a significant global public health problem with 8.7 million cases and 1.4 
million deaths due to TB reported in 2011 (1).  This has been compounded by the occurrence of 
increasingly resistant strains of Mycobacterium tuberculosis (Mtb) and the presence of HIV 
(Human Immunodeficiency Virus).  The STOP TB Partnership has set out a “Global Plan to STOP 
TB” (2006-2015) (2, 3) and a new strategy for 2015 to 2025 is currently in development. In the 
area of technological improvements, the development of new drugs, new diagnostics and new 
vaccines for TB are all proposed as strategic components towards combating TB in the Global 
Plan.  A model developed to illustrate the potential benefit of TB vaccines showed a 92% 
reduction in TB incidence by 2050 when a TB vaccine targeted at latent TB infected persons is 
combined with mass vaccinations of persons not infected with TB (4). Proposed target groups 
for new TB vaccines include infants, adolescents, HIV positive persons and HIV negative adults 
(5, 6). Adolescents are potentially an easil  accessible target through the use of a school based 
vaccination programme. Epidemiological data are crucial for planning TB vaccine efficacy trials 
but limited data has been available on the epidemiology of TB in adolescents. Such 
epidemiological data will also assist TB Control Programmes with interventions relevant to 
adolescent TB, particularly in high TB burden settings. 
In line with the stated objectives of this thesis, this literature review will describe the clinical 
features, prevalence and incidence of TB disease and TB infection in adolescents and the 
















Pubmed was searched on key words “adolescent” or “adolescence” AND “TB” or “tuberculosis”. 
Relevant articles (in English only) that were found were further reviewed for additional 
references on adolescent TB. Colleagues at collaborator institutions, the KNCV Tuberculosis 
Foundation, The Netherlands and Aeras, Rockville, Maryland, USA provided relevant literature 
on adolescent TB that they had access to. Studies which reported on adolescent TB clinical 
disease profiles, adolescent TB incidence and prevalence, and BCG vaccine trials which recruited 
adolescents were included.  Studies excluded were individual case reports on adolescents, 
studies not reporting separate data for adolescents, outbreak investigations and studies 
reporting only TB programme outcome data for adolescents such as cure, adherence, etc. 
However, where there was a dearth of data in a specific area, other studies on adolescents e.g. 
in the HIV or Human Papilloma Virus (HPV) arena or adult studies on TB, were included. It is 
acknowledged that searching on “child or childhood TB” might have drawn more studies 
showing data on adolescent TB but the number of studies involved would have been too 
impractical to review.  The search of reference lists of articles on adolescent TB would hopefully 
have drawn out the most important of these.   
The clinical profile of TB in adolescents 
Six adolescent case series found in the literature are reviewed in the section below.  Two are 
from Cape Town, a high TB burden setting and the other four are from developed country 
settings. The purpose of focusing on this aspect of adolescent TB is to clarify the clinical nature 
of TB in adolescence and to specifically determine if it is closer to TB in young children (pauci-
bacillary) or to adult type TB (cavitatory). This distinction is important for defining endpoints in 















predominant. The age and gender distributions were important to help understand 
demographic risk factors. Any gaps in the current literature could also be determined. 
The first series of 324 cases of TB in adolescents aged 10 to 18 years is the biggest and was 
drawn from primary care clinics and a dedicated TB hospital (1987-1992) in Cape Town (7). 
According to this series, most adolescents had evidence of intra thoracic TB (94%) and most had 
microbiological confirmation of disease by smear or culture (78%). Twelve percent had evidence 
of extra-thoracic TB (of whom 6% had both intra and extra-thoracic TB). Ten percent were 
described as having primary TB diagnosed mainly amongst those at the younger ages (<14 years) 
while the presence of cavitation increased with age. There was a slight predominance of females 
in the age range 13-17 years (55% female to 45% male). The authors comment on the potential 
effect of hormonal changes on the occurrence of TB given this predominance. HIV status was 
not reported but expected to be low given the low prevalence of HIV amongst pregnant women 
in Cape Town (<1%)  at the time. 
The next series of 52 adolescent TB cases who were aged 12-18 years was based on admissions 
to a hospital in France between 2000 and 2004 (8). The majority were foreign born (90%). Fifty 
two percent had isolated pulmonary disease, 31% had both pulmonary and extra-pulmonary 
disease and the remainder, 17%, had isolated extra-pulmonary disease. Sixty two percent had 
bacteriological culture confirmation of disease with 29% having had positive smears. The culture 
positive rate increased with age. Seven cases had evidence of mono-resistance. The gender 
balance amongst their cases was even - 48% female and 52% male. While a majority of cases 
were detected through the diagnosis of an ill child (67%) rather than through contact tracing 
(33%), a source case was identified in about half of cases. Seven (13%) were HIV positive of 















positive tuberculin skin test (TST) of >15 mm at diagnosis. Eighty three percent had abnormal 
chest x-rays – 70% had mediastinal lymphadenopathy, 54% parenchymal abnormalities and 26% 
had pleural effusions. Most commonly reported symptoms were fever (77%), weight loss (73%), 
weakness (72%) and cough (54%). Cavitatory disease increased with age as in the Cape Town 
series reported above. 
In a small case series of 8 patients (all pulmonary TB) aged 10-14 years seen in Cape Town at a 
primary care facility, 7 were smear positive with cavitatory disease and one had a pleural 
effusion (9). All had symptoms which included cough, chest pain, night sweats, weight loss and 
fatigue. Seventy five percent had a known TB contact within 6-18 months of presentation. There 
was a strong female predominance (6 of the 8) and none were HIV positive. This was a highly 
selective study focusing on adolescents only with pulmonary TB to illustrate the fact that 
adolescents under 14 years of age can also be diagnosed using sputum smear examinations. 
A Canadian series of 23 TB cases in adolescents aged 13-18 years seen at a hospital in Toronto 
between 1999 and 2004 has been repor ed (10). There was a female predominance (57% 
females to 43% males). Most had symptoms with cough (65%), weight loss (61%), fever (56%), 
nightsweats (39%), fatigue (34%) and bone pain (30%) being the most common. Most (21/23) 
had positive cultures, two of whom had resistant strains. All had positive TSTs. Only 5 had 
isolated pulmonary disease, 13 had extra-pulmonary disease and 5 had pulmonary and pleural 
TB. The majority were foreign born. 
An older case series of 76 cases in adolescents aged 10 to 20 years published in 1986 was 
gleaned from 3 decades of records at a hospital in New York (11). Most (58%) had evidence of 
recent or primary infection. There were no differences in gender and most cases were seen in 















cavitatory disease and 7 (9%) had pleural effusions. Ten (13%) were diagnosed with extra-
thoracic forms of TB. No resistant strains were detected. 
 A recent review by the Centers for Disease Control and Prevention, Atlanta, USA, of cases in 
children and adolescents reported to the National Surveillance System in the USA unfortunately 
does not report much data separately for adolescents but does mention that adolescents aged 
13-17 years made up just over 50% of foreign born cases under 18 years diagnosed with TB and 
that there were more TB cases amongst foreign born adolescents than US born adolescents in 
the period 2008-2010 (12). Only one third of all cases reviewed were symptomatic at 
presentation but to what extent this applies to the adolescent cases can only be indirectly 
inferred.  Cases in this series were identified either through contact investigations, investigation 
of symptoms and signs or through an incidental investigation of a presenting patient. 
In summary, with the exception of the New York series, the picture that emerges is that adult 
type pulmonary TB (infiltrative with and without cavitation) which could be confirmed 
bacteriologically is common in adolescents. However, there is an age trend with cavitatory 
disease increasing with age and the occurrence of primary TB occurring mainly at younger ages 
(The term “primary TB” remains confusing – evidence suggests that in adolescents, cavitary 
disease may follow soon after primary infection.  Young children with “primary TB” may also 
develop cavities related to progressive disease and not consistent with a “post-primary” 
phenomenon). Where specified, the smear positive proportion in general was lower than what 
is the case for adults and this has implications for screening methods for TB to be used in 
adolescents.  The data in the literature are based mainly on serious hospital level cases of TB in 
adolescents and consequently, a significant proportion of extra-pulmonary disease cases. There 















would have a different profile to cases identified through investigation of symptoms and signs in 
that the former would probably have an earlier or milder form of disease. Some series (3 out of 
5) suggest a female predominance which is interesting given that there is a male predominance 
of 1.5-2.1:1 in adulthood (13). Most cases reported were symptomatic but this is not surprising 
since most were diagnosed through presentation at a health facility rather than through 
screening of contacts or a survey. Where reported, HIV prevalence was low. In developed 
countries, most adolescent cases were foreign born. Thus, while the literature provides a 
detailed profile of TB in adolescence, the data are biased due to being mainly from hospital 
based series. This leaves a gap in knowledge with respect to community level TB in adolescence. 
This is an important gap for TB vaccine efficacy trials since such trials will be community based. 
TB Control Programmes are also more often targeted at the community level. 
TB prevalence 
TB prevalence is an important indicator of TB burden and provides a guide for resource 
allocation for TB Control Programmes. Adolescents, a high proportion of whom can be found at 
school in South Africa, represent an accessible target group for TB Control Programmes should 
the burden of TB warrant it. Thus, TB prevalence studies in this group are needed. World Health 
Organisation surveys tend not to include children under the age of 15 years (14), an important 
subset of adolescents. In addition, while surveys include adolescents 15 years and older, data 
are often not presented in a way that TB prevalence can specifically be estimated in 
adolescence. The level of exposure to active TB in a school environment is an important public 
health issue given the risks this poses to others in an enclosed setting such as a classroom. 
Finally, TB vaccine clinical trials would need to exclude TB cases at enrolment. Therefore to plan 















Very little data are available on the specific population prevalence of active TB disease in 
adolescents. A BCG trial which started in 1950 in the United Kingdom (UK) screened 58,900 
adolescents aged 14.5 to 15.5 years for TB prior to enrolment. A total of 156 were found to have 
active disease giving a prevalence of 3/1000 (15). Diagnosis was based on chest x-ray 
assessment and physician review. An older prevalence study (reported in 1936) in the pre-
chemotherapeutic era of a convenience sample of 2,381 school-going and working adolescents 
aged 14-21 years in the UK found a prevalence of TB disease as follows: 6.5/1000 when the case 
definition was restricted to chest x-ray findings definitely compatible with TB; this increased to 
11/1000 if chest x-rays probably compatible with TB were included (16). A prevalence study of a 
South Indian population in which 6,393 adolescents aged 10-19 years were x-rayed, found a 
prevalence of radiologically active TB disease of 4/1000 (17). This fell to 0.9/1000 when cases 
were required to have bacteriologically positive TB disease based on a smear and/ or culture 
done on a spot sputum but sputum tests were only done on those who had a positive chest x-
ray or did not have a chest x-ray done. The true bacteriologically positive TB prevalence in this 
latter study is likely to have been underestimated since some may have had normal chest x-rays. 
TB disease prevalence surveys which have included adolescents have been published but these 
have not separated out the prevalence among adolescents. A few of these studies on adults in 
developing countries are reported here to put the adolescent TB prevalence data into 
perspective. A TB prevalence study in Western Kenya which recruited 22,656 participants 15 
years and older found an all TB prevalence of 6/1000 with a smear positive prevalence of 
2.5/1000 (18). Half of the prevalent cases were HIV positive. A TB prevalence study done in Cape 
Town also in adults aged 15 years and older found a prevalence of bacteriologically confirmed 
TB of 10/1000 amongst 2,608 study participants from a known high TB burden area. The smear 















positive TB prevalence of 4/1000 amongst 9,000 adults >16 years, 21% of whom were HIV 
positive (19). A large prevalence survey of 38,000 persons in Eritrea found a smear positive 
prevalence of 0.9/1000 in adults 15 years and older (20). The global prevalence of TB in 2011 
was estimated by the World Health Organisation as 2/1000 while in South Africa it was 8/1000 
(1). Interestingly, the 22 high burden countries had a combined estimated prevalence also of 
2/1000. 
In summary, a few mainly old studies have reported active TB prevalence specific to adolescents 
varying from 0.9/1000 to 11/1000. Adult studies in developing countries reported similar 
prevalences varying from 0.9/1000 to 10/1000 using all TB or smear positive prevalence. One 
would have expected TB prevalence to be higher in adults. However, time and location of study 
varied between the adolescent and adult studies so comparisons between the two groups of 
studies should be viewed with caution. World Health Organisation and other survey data show 
that TB prevalence is higher in South Africa than elsewhere. Ideally, prevalence in adolescents 
should also be calculated as a proportion of overall prevalence when comparing countries since 
TB burden varies widely amongst countries; this was not possible given the dearth of data 
specific to adolescents. 
Incidence of TB in adolescence 
TB incidence data are critical to TB vaccine efficacy trial planning since these will form the basis 
of sample size estimations and therefore, the estimation of overall costs of such trials.  TB 
incidence data are also essential to TB Control Programmes in that trends over time will indicate 
whether the problem is increasing or decreasing and whether further intervention is necessary. 
Limited incidence data are available from BCG trials in adolescents. The British MRC trial which 















first 5 years of the study in the BCG unvaccinated group who were TST negative at baseline (15). 
A similar rate was found in those who were TST positive (induration diameter >15mm) at 
baseline. Those who were vaccinated with BCG at study entry (in adolescence) had a rate of 
0.4/1000. A second trial of BCG amongst Puerto Rican children aged 1-19 years, found an 
average annual TB incidence rate of 0.9/1000 amongst those aged 13-18 years at enrolment 
who had a positive TST at baseline during a mean 19 year follow up period (21). The trial of BCG 
revaccination conducted more recently in participants aged 7-14 years in Brazil found a rate of 
0.3/1000 person years (22). De Pontual et al. reported a stable annual incidence of TB in 
adolescents in France of 0.036/1000 in adolescents of French origin while there was an increase 
from 0.3/1000 to 0.83/1000 amongst foreign born adolescents between 1991 and 2001 (8). 
They reported an increase in the annual TB case notification rate from 0.1/1000 in 1988 to 
0.12/1000 in 1999 amongst adolescents in the poor area in Paris served by their hospital. The 
World Health Organisation reported a 1.25/1000 all ages global incidence rate for 2011 with 
2.62/1000 in the Africa Region, 0.28 in the American Region and 0.42/1000 in the European 
Region (1). The estimated all ages incidence rate in South Africa was 9.93/1000. 
In summary, limited specific data on TB incidence in adolescents are available. The overall 
incidence rate is higher in Africa than in Europe and America and it should be expected that 
rates of TB in adolescents in Africa will also be higher than those reported from studies in 
Europe and South America. Again, caution will be need to be exercised in comparing incidences 
in adolescents amongst countries since these will be related to the overall TB burden in each 















Age distribution of active disease 
TB vaccine efficacy trials in adolescents will need to be powered adequately in terms of number 
of cases to be accrued but would need to include the population at whom the vaccines will 
ultimately be targeted i.e. as early in age as possible prior to the upswing in incidence which 
occurs during adolescence. Thus age trends in incidence of TB in adolescents are important to 
determine. Since the risk of TB is age dependent, TB Control Programmes will need to know 
which age groups are at highest risk.     
The age distribution of TB cases in Cape Town in HIV negative persons has bee  described based 
on routine data. These show peaks in young children and adulthood and a rising incidence in 
adolescence (23) as shown in the figure below (permission for the use of this figure was received 
















Donald et al. describe a hypothetical age and gender distribution in a high burden setting 
compared to a low burden setting; what is observed is that the age distribution seen in the Cape 
Town data shown above is typical of high burden settings (24). A review of TB notifications in 
1980 in Finland showed incidence rates of 10-14 year olds and 15-19 year olds of 0.040/1000 
and 0.066/1000 respectively (25). The Finnish authorities stopped the BCG revaccination 
programme in 1990 after a steady decline in overall TB incidence but this did not impact on the 
downward trend in overall TB incidence and  in 1995, incidence rates were 0.006/1000 and 
0.012/1000 in 10-14 year olds and 15-19 year olds respectively (25).  These rates are much 
lower than those in developing countries as given in the WHO report mentioned above (1). A 
second report looking at data from Sweden and Finland showed the highest rates in those over 
65 years in indigenous Swedes and Finns while foreigners living in Sweden and Finland had a 
peak in the adult age range of 15-64 years (26). The occurrence of disease in adolescents is likely 
to have been due to recent infection whereas the disease in those over the age of 65 was more 
likely due to reactivation disease. 
In summary, adolescence is a period of rising TB incidence particularly in developing countries. 
Where a rising TB incidence in adolescence is seen in developed countries, this is due to foreign 
born persons. 
Latent TB infection 
Latent TB infection represents an important entity in that it provides evidence of exposure to 
Mtb and represents an increased risk of progressing to active TB disease.  In TB vaccine trials, 
there has been a concern that giving new vaccines containing TB antigens may be harmful to 
individuals who are latently infected with TB. In addition, new TB vaccines are designed to be 















the nature of this state and its prevalence is therefore warranted in the context of the 
epidemiology of TB in adolescents. 
The pathogenesis of TB is described as follows: exposure to Mtb which may lead to latent 
infection which may then lead to active TB disease which in turn leads to recovery, chronic 
infection or death (27). The above (27) illustrates the evolution of TB well. Latent TB infection is 
a state which follows on exposure to Mtb. It is described as a quiescent state maintained by the 
immune response which prevents replication and tissue damage (28). Its significance lies in the 
fact that it represents evidence of exposure and that a proportion of those with latent TB 
infection progress to active TB disease through re-activation of this latent state. Evidence for the 
existence of this state comes from post mortem studies of persons dying of unrelated reasons in 
whom live Mtb bacilli were found. One third of the world’s population is estimated to be 
infected with Mtb (28). It is acknowledged that a large literature on TST positivity from the last 
century exists even if not referenced in this thesis. 
Historically, the TST  (Mantoux) test was used to measure the presence of this latent state (29). 
The test was developed as a diagnostic tool by Robert Koch in the late 19th century and has gone 
through an evolution in its use. Essentially it involves the application of Mtb proteins to the skin 
or injection into the skin. Current recommended use involves the injection of a specific dose of 
an internationally standardized “purified protein derivative” or PPD of Mycobacterium 
tuberculosis intradermally into the volar surface of the forearm (30, 31). The size of the reaction 
to this injection is read 48 to 96 hours later by measuring the amount of induration at the site of 
injection in millimetres. Pre-defined cut-offs are used to interpret the result (30).  Alternatively, 















Lack of specificity has long been a problem with the TST in that the vaccine BCG and non 
tuberculous mycobacteria (NTMs) also induce a response to the TST injection (32). This has led 
to the development of interferon gamma release assays (IGRAs) which focus on the so-called 
“region of difference” which utilise antigens of Mtb which do not occur in BCG and most NTMs 
(33). Two commercial interferon gamma release assays are available, the QuantiFERON TB 
assays (Cellestis, Victoria, Australia) and the T-SPOT.TB (Oxford Immunotec, Oxford, United 
Kingdom). Besides the advocated increased specificity, the advantages of these tests are that: 1) 
they require a single visit while the TST requires two, 2) repeated measures do not result in 
boosting which does occur with the TST and 3) the result is objective as it is generated in vitro 
whereas the TST requires human measurement which is prone to error or inter and/or intra 
reader variation. However, these assays are more expensive and require a sophisticated 
laboratory infra-structure and skilled laboratory staff.  
IGRAs have been evaluated extensively over the past decade or more to determine their 
comparability or superiority to the TST (34). One area of specific interest has been the predictive 
value of IGRAs for TB disease. The patient with a positive TST has an established risk of 
progression to active TB disease (35). Specifically in adolescents in the British MRC BCG trial, 
those with strong TST reactions at enrolment had a high attack rate within two years of entry 
(36). Furthermore, amongst those who converted from a negative TST to a positive TST during 
the trial, 5.2% developed TB disease (all types) during follow up with 80% of cases occurring 
within the first two years after conversion.   
Whether IGRAs have the same predictive value as TST has been the subject of a number of 
investigations (37-42). All these studies found IGRAs to be predictive of an increased risk of 















be superior to the TST in predicting TB disease onset (37, 38, 40) while Kik et al., Hill et al. and 
Lienhardt et al. did not (39, 41, 42). The reasons for the differences are not clear but may be due 
to poor reading technique of the TST, varying environmental prevalences of NTMs or use of 
different TST cut-offs. These results are relevant to the question of whether IGRAs should 
replace the TST in clinical trials of TB vaccines or in clinical practice. Most of these studies were 
based on household contact investigations while only one was based on a cohort study (40).  
More population based cohort data on IGRAs are needed to guide what should be used in 
clinical trials which are by their nature population based.  
The relevance of latent TB infection to TB vaccine trials is twofold. In the first place, Robert Koch 
soon after he discovered Mycobacterium tuberculosis tried to administer a protein extract from 
the organism, tuberculin, as a form of treatment for active TB disease (43). It was found in 
certain instances that tuberculin aggravated the course of disease. Based on these outcomes, 
the concern with new TB vaccines is that the administration of TB antigens through these 
vaccines may result in negative consequences should they be administered to individuals with 
latent TB infection or active TB disease (Koch Phenomenon). New TB vaccines are first tested in 
individuals in whom latent TB infection is absent and are then usually tested in small groups of 
latent TB infected persons to establish their safety as part of product development. Screening 
for latent TB infection is thus an important part of pre vaccination evaluations in safety trials of 
new TB vaccines.   
Secondly, latent TB infection is also important because latently infected individuals have a 
higher risk of progressing to TB (35). Latently infected individuals are thus an important target 















TB burden context will need to have been evaluated in latently infected persons since a high 
proportion of adults/ adolescents will already be latently infected at the time of vaccination. 
Limited data are available on the presence of latent TB infection in adolescents. Middelkoop et 
al. conducted a TST survey in 831 children aged 5-17 years in 2006-2007 in a high TB and HIV 
burden township in Cape Town, South Africa (44). Using a 10 mm cut-off, they found a 
prevalence of latent TB infection of 45.1% in children aged 12-13 years and 52.5% in children 
aged 14-17 years, with increasing age being a significant predictor of latent TB infection. A 
follow up survey by the same research group at a secondary school in the same community 
found a latent TB prevalence of 53.9% in an age range of 13-22 years amongst 620 HIV negative 
participants (45). In this latter paper, the authors introduce the concept of “force of infection”. 
Force of infection is calculated by showing the change in latent TB infection prevalence between 
age groups. They show adolescence to be a period of high “force of infection” because of a 
change in this prevalence between age groups during adolescence of between 5 and 7%. This 
concept differs from annual risk of TB infection (ARTI) in that force of infection quantifies the 
change in infection prevalence from the prior year whereas ARTI describes average annual risk 
of infection since birth. In the adolescent group where force of infection was studied, a positive 
TST was associated with age and male gender.  
The BCG trial in adolescents in the United Kingdom which recruited 56,700 adolescents from 
1950-52 conducted TSTs at recruitment and found the following (after exclusions) (15): 60% 
were TST negative, 28% were TST positive based on the administration of 3 tuberculin units 
(TUs) and a further 12% who were initially TST negative after the administration 3 TUs, were 
then positive after the administration of 100 TUs. The 40% TST positive proportion assumed to 















to TB through a household contact were excluded from study entry and did not reach the stage 
of TST testing. A South Indian prevalence survey amongst a population of 35,000 published in 
1963 found a prevalence of latent TB infection amongst those aged 10-19 years of 33% (17). A 
study in New York, USA found a prevalence in 1991-1993 of 11.5% to 23.3% in school entrants 
aged 12-16 years (46). Another study from the same period found prevalences of 12.8% and 
24.1% at two high schools in San Diego, USA (47). Being of foreign origin was a major predictor 
of a positive TST in these two USA studies. US guidelines on targeted tuberculin testing 
recommended middle and high schools as ideal places for such testing because prevalences 
were higher amongst adolescents than younger children (48). Prevalence in Rotterdam, The 
Netherlands in 1967 to 1968 was 0.03% in adolescents aged 10 -19 years as derived from data 
based on tuberculin surveys over a three year period (49). 
In summary, latent TB infection is an important condition in the TB context and is relevant to 
both TB Control Programmes and TB vaccine trials. Both the TST and IGRAs are used to measure 
latent TB infection and both have advantages and disadvantages. Studies of the predictive value 
of IGRAs compared to TST for TB disease have shown varying results but these studies have 
been done mainly in contacts of TB cases. Prevalence of latent TB infection is lower in low 
burden settings such as the US, where being of foreign origin was a major risk factor, and The 
Netherlands. High prevalences were found in high burden settings as seen in the Cape Town and 
South Indian study. A relatively high prevalence was reported in the UK BCG trial but this dates 
back to a time when the TB burden was high there. In general, limited data on the prevalence of 
latent TB infection in adolescents are available in the literature particularly from high burden 
settings. Comparisons between countries and studies are limited by variations in time of study 















Screening for TB 
Screening for certain diseases is now a routine part of health care as a means of early detection 
leading to early treatment and a resultant reduction in morbidity and mortality for that disease 
(50, 51). Screening is also important for clinical trials where persons with certain illnesses or 
conditions need to be excluded or included in trial participation. For screening to be effective, 
screening tools need to be both sensitive and specific i.e. be able to detect as many cases of 
disease as possible but also to minimize positive screening test results not due to the condition 
being tested for (false positives). 
As described by Hennekens and Buring, besides the sensitivity and specificity of screening tools, 
the diseases being screened for should meet certain criteria (50): 1) the disease should be a 
significant public health problem in respect of disease severity and risk of mortality, 2) 
treatment prior to disease onset should be beneficial, and 3) it should be a highly prevalent 
condition.  
Wilson and Jungner summarised 10 criteria for screening to be  worthwhile as a public health 
intervention (51) which are simila  but more detailed. These are set out in Table 1.  
Table 1: Prerequisites for successful screening 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with the disease. 
3. Facilities for diagnosis and treatment should be available.  
4. There should be a recognizable latent or early symptomatic phase. 
5. There should be a suitable test or examination. 















7. The natural history of the condition should be understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost should be economically balanced in relation to possible expenditure on medical 
care as a whole. 
10. Screening should be a continuing process and not a short lived project. 
 
With respect to screening for TB disease specifically, this is important for both public health care 
services and for clinical trial investigators. Public health services would like to detect TB early to 
minimize morbidity and mortality due to TB and to prevent the spread of disease to others as it 
is an infectious condition. For those involved in TB vaccine clinical trials, screening for TB is 
important for exclusion at baseline should active TB be an exclusion criterion, but also to detect 
TB disease during follow up for efficacy trials of new TB vaccines. Since there is no correlate of 
protection for TB vaccines, the measurement of clinical outcomes such as TB disease is the only 
way in which vaccine efficacy can currently be measured (5). 
The WHO has developed an approach to screening for TB in prevalence surveys and three 
algorithms are offered: 
1) Symptom and chest x-ray screening on all. Those with symptoms or abnormal chest x-rays are 
referred for a sputum smear and culture.  
2) Symptom and chest x-ray screening, and sputa taken for smears on all. Cultures are only done 
if any of the former are positive.  















These range from the more affordable option, 1, to the more expensive option, 3. There is, 
however, a loss in sensitivity with the less expensive methods of screening. Options 2 and 3 also 
require substantial laboratory capacity because large numbers of cultures would need to be 
performed. Option 3 would not miss any cases except perhaps pauci-bacillary cases amongst 
HIV positive persons (and younger adolescents if used for adolescent screening, as they more 
often have pauci-bacillary disease compared to older adolescents) while option 1 would miss 
smear or culture positive cases without symptoms or chest x-ray abnormalities, and option 2 
would miss smear negative, culture positive cases without symptoms or chest x-ray 
abnormalities (this may also be a factor in younger adolescents). 
Data from surveys in different countries on varying target populations support differing 
screening strategies. A survey in which 1,170 adults in a high burden TB community setting in 
Cape Town were screened, found any abnormality on chest x-ray to be highly sensitive for 
bacteriologically positive TB (97%). However, a positive predictive value derived from the data 
provided was low at 6% (52). The authors found symptoms to have a low sensitivity (all less than 
60%). A study in Kenya in 7,342 HIV positive and uninfected participants also found chest x-rays 
to be highly sensitive for bacteriologically confirmed TB (94%) but the derived positive predictive 
value was low at 2% (53). Individual symptoms had low sensitivities but “any TB symptom” (at 
least one) had a sensitivity of 90%. This later study compared their findings with other studies 
and found “any TB symptom” to have variable sensitivities, “cough” to have a low sensitivity but 
x-ray abnormalities to generally have high sensitivities. Differences in findings were reported as 
being due to cultural differences, differences in study design or population studied or due to 















In summary, screening for TB disease in adolescents is important for TB vaccines trials and 
would be relevant to TB Control Programmes should they consider programme interventions 
specifically for adolescents. No data on screening for TB specifically in adolescents in a 
community setting was found. While most general surveys start at age 15 years, data specifically 
for the adolescent age component was not found. Two surveys in high burden settings in adults 
found chest x-rays to be sensitive tools for detecting TB while the sensitivity of symptoms 
varied. Positive predictive values were low for all screening methods in these surveys. 
Readiness to participate in TB vaccine trials 
Adolescence represents a unique development stage, physically and psychologically. Vaccination 
in adolescence provides an opportunity for prevention (54). The increasing incidence of TB in 
adolescence (23), the high force of TB infection in adolescence (45) and the fact that adolescents 
are an accessible population through schools make them a feasible target for new boost TB 
vaccines.  Both safety and efficacy trials would need to be conducted in this group. It was not 
clear how willing they would be to participate in TB vaccine trials. Their level of knowledge of 
TB, vaccines and clinical trial research may influence such participation but this was unknown.  
Adolescents have been the subject of two very large clinical trials of BCG (15, 22).  One starting 
in 1950 in the United Kingdom recruited 58,000 adolescents aged 14.5 to 15.5 years (15) and 
one in Brazil which recruited 240,000 school children aged 7-14 years (22).  In the Brazilian trial 
where participation was on an “opt out” basis, one quarter of children were absent on the day 
of vaccination giving an indirect indication of participation rate but absence may have been due 
to other reasons. In the British trial, 60% agreed to participate but reasons for non-participation 
were not provided (15). BCG is however a registered vaccine and is known, and participation in 















No data were found on knowledge and attitudes in general or specifically amongst adolescents 
towards TB and willingness to participate in TB vaccine trials. These questions have been 
examined in the HIV arena. An investigation into adolescents’ willingness to participate in HIV 
vaccine trials in a peri-urban community in Cape Town found that 79% were definitely or 
probably willing to participate in such trials (55). Increasing age, being sexually active and length 
of residence in the community were significantly associated with willingness to participate. The 
main reasons given for willingness to participate were to help find a vaccine to protect their 
loved ones but also a hope that the vaccine would protect themselves from HIV. A study on 
community attitudes towards HIV vaccine trials in adolescents revealed concerns about consent 
and confidentiality of procedures (56). The ethical and legal challenges of including adolescents 
in research on HIV have been highlighted but it has been argued that it is important for this 
group to be included while ensuring that they are protected from harm (57). A review of studies 
on knowledge of HIV/AIDS amongst youth (aged 14-35 years) in South Africa found a high 
awareness of AIDS as a sexually transmitted disease which was fatal (58). The youth were less 
knowledgeable about HIV transmission and methods of prevention. 
Since Human Papilloma Virus (HPV) vaccination is under consideration for adolescents, 
knowledge and attitudes surveys on this vaccine were reviewed. A survey of parental and 
adolescent knowledge and attitudes on HPV vaccination in Finland was published in 2007 (59). 
The postal survey of 1,990 adolescents and their parents had a low response rate of between 
20% and 40%. Of those who responded, 83% of adolescents and 86% of parents were willing to 
accept HPV vaccination of adolescents. Low knowledge of HPV and general concerns about the 
safety of vaccinations were associated with unwillingness to undergo vaccination. A telephonic 
survey of women in Kentucky in the USA showed women to be interested in vaccination for 















heard of HPV (60).  Acceptability of young girls being vaccinated decreased with age. 
Interestingly, higher education and higher income were associated with lower acceptability. 
In summary, adolescent participation in 2 BCG trials have varied from 60 to75% but these 
numbers may not be representative of future participation in trials of experimental TB vaccines. 
Knowledge and attitudes may influence participation in TB vaccine trials but no data was 
available on this in general or specifically for adolescents.  Data from the HIV and HPV arenas 
suggest that adolescents are interested in HIV and HPV vaccine trials but there are legal and 
ethical obstacles, safety concerns and lack of knowledge that would need to be overcome. 
Gaps in the literature linked to thesis objectives 
This literature review has provided an overview of literature available on TB in adolescents 
relevant to this thesis but has revealed certain gaps. Limited data are available on the 
prevalence of latent TB infection specifically in adolescents.   Very few studies have reported on 
TB disease population prevalence in adolescents. While the TB disease profile in adolescents has 
been examined in a number of studies, this has come mainly from hospital based series with 
limited data on adolescent TB as seen at a community level. Few studies have reported on TB 
incidence in adolescents. In general, most data on adolescence has come from developed 
countries rather than developing country settings. Many of the data are quite old with very few 
recent studies on adolescents. With respect to IGRAs, data are mainly from developed countries 
while it has been reported that these tests behave differently in high TB burden settings. No 
data on the use of IGRAs in adolescents have been reported. No data on screening approaches 
for TB in adolescents was found. No data on attitudes of adolescents towards participating in TB 
vaccines trials have been published although some data on adolescent attitudes towards HIV 















objectives set for this thesis will provide a useful contribution to the scientific literature on 
adolescent TB.  
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Chapter 3: Predictive factors for latent tuberculosis infection among 
adolescents in a high burden area of South Africa. 
 
Paper overview 
This analysis reports on the baseline prevalence of latent tuberculosis (TB) infection in the 
adolescent cohort that was studied as measured by both the tuberculin skin test and an 
interferon gamma release assay.  The predictive factors for a positive test by either measure is 
shown as evaluated through a multivariate analysis. 
Contribution to the thesis and novelty 
This paper addresses the first objective of the thesis. As shown in the literature review, little 
data on the prevalence of latent TB infection are available for adolescents with none using the 
interferon gamma release assay. Little data on predictive factors for latent TB infection in 
adolescents were found.  Such data will be of enormous value for those planning trials of TB 
vaccines in adolescents and for TB Control Programmes. 
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Setting: A high tuberculosis (TB) burden area in South Africa (notification rate for all TB cases 
1400/ 100 000). 
Objective: To determine the prevalence of and predictive factors associated with latent TB 
infection in adolescents. 
Design: Adolescents aged 12-18 years were recruited from high schools, clinical and 
demographic data were collected, and a tuberculin skin test (TST) and a QuantiFERON® TB GOLD 
In-Tube (Cellestis) (QFT) assay performed.  
Results: 6,363 (58.2%) of 10,942 adolescents at the schools were enrolled. After exclusions, of 
5,244 participants, 55.2% (95% confidence interval 53.8 -56.5) had TST > 5 mm, while 50.9% 
(49.5 - 52.2) were QFT positive. On multivariate analysis, Black/ Mixed Race racial groups, male 
gender, older age, household TB contact, low income and low education level were predictive 
factors for both TST and QFT positive results.  
Conclusion: About half of adolescents were found to be latently infected with TB in a high TB 
burden area with demographic and poverty related socio-economic factors predicting the risk of 
tuberculosis infection. Adolescents from deprived communities should be considered an 
important target group for educational interventions by TB Control Programmes in high burden 
settings. 
 


















It was estimated that 9.3 million people developed tuberculosis (TB) disease and 1.8 million died 
from the disease in 20071. Despite this huge burden, very little has been published on 
adolescent TB2-5. Compared to younger children, this group has a rising incidence of TB disease 
with age, as shown in unpublished data from Cape Town drawn from routine TB notifications 
(figure 1). The increasing incidence with age may reflect an increasing susceptibility to TB 
disease due to a higher risk of TB infection. In order to prepare for future phase III trials of new 
vaccines in adolescents, our aim was to determine the epidemiology of latent TB infection in 
adolescence in the Worcester region, outside Cape Town, South Africa. This area has a high 
notified TB incidence rate among all ages of approximately 1400 per 100 0006.  This agricultural 
area has an unemployment rate of 20% with 50% of those employed earning < $100 per month 
(South African National Census 2001). New smear positive TB rates ranged between 454 – 631/ 
100 000 between 2000 and 2004. The main objective of this study was to determine the 
prevalence of and predictive factors for latent TB infection among adolescents from this region. 
   
Traditionally, the tuberculin skin test (TST) has been used to detect latent TB infection. Unlike 
the TST, which uses purified protein derivative (PPD) of Mycobacterium tuberculosis as antigen 
which is widely cross-reactive, antigens used in the newer interferon gamma release assays 
(IGRAs) are mostly specific to M. tuberculosis. These tests have been promoted as an alternative 
to the TST, as results should not be affected by prior exposure to BCG nor other non-tuberculous 















where BCG vaccination coverage is high10. This is the first study that we are aware of that 
examines predictive factors for TB infection using both the TST and an IGRA in adolescents. 
Study Population and Methods 
 
Study setting: The study took place in the town of Worcester (and surrounding villages), 
approximately 100 kilometres from Cape Town, South Africa.   
Study participants: All adolescents aged 12-18 years attending all 11 public high schools in the 
study area were approached to participate. 
Study procedures: At enrolment, a questionnaire was administered to study participants and 
their parents to collect demographic and socio-economic data. These included parental income 
and parental education. The racial classification of participants “White”, “Mixed race”, “Indian” 
and “Black” was based on a system used in the apartheid era, but still used today as a proxy for 
socio-economic status and to measure social change.  History of BCG vaccination (reported), 
history of current and past TB disease, current and past TB household contacts, hospitalization 
in the past 6 months and information on chronic diseases were obtained. Participants were 
examined for the presence of a BCG scar. 
 
Blood was taken for QuantiFERON® TB Gold In-tube (Cellestis, Victoria, Australia). A TST was 
then immediately administered using the Mantoux method on either forearm, using 2 
tuberculin units of RT23 (Statens Serum Institut, Denmark).  Induration at the TST site was read 
48 - 96 hours later with a ruler or a caliper, by trained study personnel. Those with previous or 
current TB did not have a TST performed, in order to prevent severe allergic reactions. The 















Data analysis and statistical considerations: 
The sample size required to find a predictive factor for infection present in at least 25% of the 
population, with an odds ratio of 1.2, a power of 80% and alpha of 0.05, was estimated to be 
5,200.   
 
Data were captured in a Microsoft Access database, and analysed with Stata version 11.0 
software (Quantec, Pretoria, South Africa). To ensure the integrity, validity and quality of data in 
the database, the following measures were put in place: Only trained data entry personnel were 
used with controlled access to the database. Normalization, referential integrity and data 
validation rules were implemented during database design. Data was verified and validated 
prior, during and after data entry according to a data entry standard operating procedure (SOP). 
An internal data monitor periodically reviewed a random 10% sample of case report forms 
(CRFs) entered on the database according to SOPs. Additionally, she reviewed all the CRFs 
entered on the database at the end of the study and corrections made accordingly. 
 
Univariate and multivariate analyses were performed.  Statistical significance was determined to 
be present at p <0.05, or if confidence intervals did not cross one. A TST cut-off point of 5 mm 
was the default threshold used for analysis based on the frequency distribution of TST 
indurations which was not bimodal, although cut-off points of 10mm and 15 mm were used for 
certain analyses. For the purposes of analysis, Indian and White participants were grouped 
because they shared similar socio-economic profiles. For analysis of income, a cut-off was set at 















which category the adolescent was placed in.  Education level was divided by primary school or 
less and secondary school or more. 
Ethics: This study was approved by the Faculty of Health Sciences Human Research Ethics 
Committee of the University of Cape Town. Written informed consent was obtained from the 




6,363 adolescents aged 12-18 years (58.2%) were enrolled into the study, from a total of 10,942 
adolescents attending the schools at the time of enrolment (2006 data supplied by the 
Department of Education). Enrolment rates ranged between 22.2% and 74.2% among schools, 
with those within communities with lower socio-economic status having higher enrolments. 
Reasons for non-enrolment included parental refusal, adolescent refusal, out of age range, 
inability to locate the participant, lack of availability of the parent or guardian for consent. Fear 
of needles was the reason most commonly provided when a reason was given for refusal. The 
proportion of females enrolled (54%) was greater than in the source population where the 
proportion of females was about 50% suggesting that proportionately less males enrolled than 
females. Not enough data was collected on “fear of needles” to specifically indicate if this was 
the reason why proportionately less males enrolled in the study. 
 
The focus of analysis was on participants with both a TST and QFT result. Those with an 
indeterminate QFT result (n=13) were excluded. Since we did not give a TST to those with past 















study procedures (n=21). As n=702 did not have a TST result, n=309 no QFT result, and some of 
these categories overlapped, this left n=5,244 (82.4% of total enrolled) participants for analysis. 
We did an additional analysis which included those with current or past TB (n=673) where the 
sample analysed was n=5,917.  
 
The demographic profile of the enrolled participants is shown in Table 1. There was a small 
female predominance amongst enrolled participants (54.2%), compared with the source 
population (49.7%).  
 
The prevalence of latent TB infection 
Figure 2 shows the distribution of TST induration diameters (excluding 0 mm), which had a peak 
(mode) at 12 mm. There is no obvious sign of digit preference. 
 
A total of n=2,894 out of n=5,244 participants, or 55.2% (95% confidence interval [CI] 53.8 -
56.5%), had a TST >5 mm, while n=2,669 or 50.9% (49.5 – 52.2%) of participants had a positive 
QFT. A total of n=2,214 out of n=5,244 participants, or 42.2% (95% CI 40.9 -43.6%), had a TST 
>10 mm and when 15 mm was used as the cut-off, n=981, or 18.7% (95% CI 17.7-19.8%) were 
TST positive. There was good agreement at 5mm (% agreement 84.8%, kappa 0.70 [95% CI 0.68-
0.71]) and 10 mm TST cut-off (% agreement 81.4%, kappa 0.63 [95% CI 0.61-0.65]) but not the 
















An additional analysis where we included those with current or prior TB gave a prevalence of 
latent TB infection with TST > 5 mm of 60.3% (n=3,567/5,917 [95% CI 59.0 - 61.5]) and QFT of 
53.7% (n=3,174/5,917 [95% CI 52.4 - 54.9]).  
 
Predictive factors for latent TB infection 
Significant predictive factors for latent TB infection as measured by both TST and QFT on 
univariate analysis were older age, Black and Mixed racial groups compared to White/ Indian 
racial groups, low parental income, maternal and paternal education at primary school level or 
less, current or prior household TB exposure and absence of chronic allergic disease (Table 1). 
 
A multivariate model was developed including only the statistically significant associations from 
univariate analysis (Table 2) except that gender was added since this is a known risk factor for 
TB in adulthood. The following predictive factors were predictive of TB infection for both TST 
and QFT: Black and Mixed racial groups, age >15 years, household TB contact, parental monthly 
income <R4,000 (~$500), maternal education primary school or less and male gender. In 
addition, absence of chronic allergic related diseases was significantly predictive of a positive 
QFT test only.  
 
% QFT positive by age and gender 
% QFT positive is shown by TST induration status by age and gender (Table 3). Interestingly, 















>15mm TST group. A further elaboration of the relationship with age is shown in Figure 3 which 




We found more than half of adolescents to be latently infected with TB in a predominantly low 
income, high TB prevalence population using two different measures of latent TB infection. 
Many demographic and socio-economic variables were predictive of latent TB infection, even on 
multivariate analysis. Predictive factors were similar using both measures. QuantiFERON did not 
show any significant advantage over TST in this study. 
 
A survey amongst grade 9 (age 14-15) Norwegian students found a TST positive proportion of 
only 1.6% of whom only 9% were QFT positive12. A study of the children of immigrants aged 4-18 
in Canada found 21% to be TST positive5. In contrast, a study of a community with a high 
prevalence of HIV amongst adults in Cape Town showed a 52.5% TST positive level amongst 
adolescents aged 14-1713.  These differences probably reflect differences in community 
exposure to infectious TB. 
 
A higher latent TB infection prevalence was found when we included those with prior or current 
TB. This may be more representative of the total population because those with current or prior 
TB are likely to be a higher risk group for infection. (The inclusion of those with current TB in this 
analysis, means that this group cannot be defined as only latently infected. Strictly speaking, 
















The absence of an association between TST and BCG is in line with the conclusions of Farhat et 
al. who found that the BCG effect on TST is minimal in a situation where BCG is given at birth (as 
in South Africa) and the TST is done more than 10 years thereafter9. It is surprising nevertheless 
that no impact of BCG is seen in these data given that IGRAs are promoted as being more 
specific and not being affected by BCG and most NTMs. The study in Cape Town in a high HIV 
prevalence community also found no association between the presence of a BCG scar and TST 
positivity13. 
 
Since QFT is considered a more specific test than TST, a lower proportion of QFT positives than 
TST positives is expected10 and this has been found in other studies12, 14, 15. However, different 
TST cut-offs give different prevalences for latent TB infection. An examination of the TST 
distribution should guide determination of the cut-off as well as the use of methods such as 
mixture analysis. 25% of children deemed positive by virtue of the 5 mm cut-off were in the 5-9 
mm range. Of these 64% were QFT positive. The fact that the majority were QFT positive 
supports the use of this cut-off as an indication of genuine latent TB infection. The 36% who 
were QFT negative is however a substantial proportion – either this is an indication that the QFT 
was not sensitive enough to detect latent TB infection in this group or that the TST cut-off 
misclassified these children as latently infected. Further exploration of this is needed to 
















History of TB contact and older age were expected to be predictive factors for latent TB 
infection. Socio-economic markers (lower parental income, fewer years of parent education) 
were demonstrated to be significant predictive factors, confirming that TB is rooted in poorer 
communities1. Origin outside of a Western country and history of exposure to TB were reported 
as predictive factors for a positive QFT in Norwegian adolescents12. 
 
The strongest predictive factor for TB infection was racial group, even in a multivariate analysis 
including income and education. However, it is likely that socio-economic status is not fully 
captured by the income and education variables. Another study in South Africa showed that 
when a number of socio-economic factors were taken into account using a multivariate model, 
racial group disappeared as an independent predictive factor for TB disease16. 
 
Male gender was shown to be a significant although weak predictive factor for a positive TST 
and QuantiFERON test on multivariate analysis. This was shown also for QFT in another study in 
adults in this area17. Males have higher rates of TB disease in adulthood18-20. There appears to be 
a difference in risk of TB infection by gender with age, with adolescence representing a 
transition phase between childhood and adulthood21.  
 
The reporting of allergy related conditions was associated with a lower prevalence of TB 
infection as measured by QuantiFERON. There is some evidence of an inverse relationship 

















The relevance of this study for TB control managers is that it shows that more than half of 
adolescents have latent TB infection in a high burden setting linked to socio-economic status 
and household exposure. This may be an important target group for educational programmes 
on TB to enhance early detection. 
 
Representivity of this sample may be limited because of non-agreement to participate by 42% of 
school children. As the main reason given for refusal to participate related to “fear of needles”, 
the impact on these analyses may be unbiased with respect to latent TB infection. According to 
the South African Census held in 2001, 80% of children aged 12-18 years were at school in this 
community. As school dropouts are likely to represent a higher risk group for TB, the infection 
proportion may be underestimated. On the other hand, there were higher study enrolment 
rates at lower socio economic status schools, and this is likely to have caused an over estimation 
of the infection risk. Nevertheless, we feel that the prevalences measured in this study are likely 
to be close to the true population prevalence in this age group in predominantly low income 
high TB incidence communities in South Africa. HIV testing was not done for this sub-study. This 
area of South Africa has much lower HIV sero-prevalence than the overall national prevalence 
according to annually conducted HIV prevalence surveys in South Africa (5-10% amongst 
pregnant women compared to 30% at national level). HIV infection is thus expected to be low in 



















The prevalence of latent TB infection in this adolescent population as measured by TST and QFT 
was 55.2% and 50.9% respectively. Racial group is a strong predictor of TB infection in this 
community and this is likely to represent a proxy for socio-economic factors other than those 
measured. The predictive factor profile for both measures was similar.  
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8.65 (6.35; 11.82) 




8.8 (6.3; 12.4) 
9.6 (6.9; 13.2) 
Parent income:  classified on at least one parent’s income 
<R4000 /month  



























Maternal highest education level 
< Primary school  













Paternal highest education level 
< Primary school  













BCG reported as being given 
No  
Yes (ref)  
Unknown  
46   (0.9%) 
4,917 (93.8%) 












Unknown (Not sure)  
1,490 (28.4%) 







50.8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
1.01  
(0.89; 1.16)





























Chronic allergy-related conditions e.g. asthma, hay fever, eczema 
Yes  
No (ref)  










History of hospitalization within the 6 months prior to enrolment 
Yes 











1Tuberculin Skin Test positive (> 5 mm induration) 
2OR=odds ratio 
3”Unknown” excluded from OR calculations 
4 QuantiFERON TB Gold positive >0.35 international units 


























 TST  QFT  
Racial group (mixed race) 4.2 3.1 – 5.7 4.9 3.5 – 6.9 
Racial group (black) 3.9 2.8 - 5.4 3.8 2.7 – 5.5 
Current or prior TB household contact 2.0 1.7 – 2.3 1.9 1.7 – 2.2 
Income <R4000/ month 1.5 1.2 – 1.8 1.6 1.3 – 1.9 
Maternal highest education level – 
<Primary school 
1.7 1.5 – 1.9 1.5 1.3 – 1.7 
Age (years) >15 1.4 1.3 – 1.6 1.4 1.2 – 1.5 
Paternal highest education level – 
<Primary school 
1.2 1.0 – 1.5 1.1 0.9 – 1.4 
Gender - Male 1.12 1.0 – 1.3 1.2 1.0 – 1.3 
Chronic allergy- related conditions   0.4 0.2 – 0.9 

















Table 3: % QFT positive by TST induration group by age and gender 
 
  
TST induration group 
Age Gender < 5mm  5 - 9 mm  10 -14 mm  >15 mm 
13 Female 11.9 13.7 38.7 35.7 
 
Male 13.9 16.5 44.3 25.2 
14 Female 10.8 14.8 40.1 34.3 
 
Male 13.0 13.4 44.6 29.0 
15 Female 10.4 17.6 38.1 33.9 
 
Male 10.0 16.0 40.3 33.7 
16 Female 9.8 12.5 39.4 38.2 
 
Male 9.2 19.2 40.2 31.4 
17 Female 12.5 14.8 35.2 37.5 
 
Male 11.9 13.4 40.6 34.2 
18 Female 8.1 25.2 34.2 32.4 
 

















Figure 1 All TB incidence rate by age (years) in Cape Town, July 2002 to June 2003 (N=5039) 
 
 


















Figure 2 TST distribution amongst adolescents aged 12-18 years (N= 5244)* 
 
































































Chapter 4: Screening for TB in high school adolescents in a high burden 
setting in South Africa 
 
Paper overview 
This analysis reports on the prevalence of TB disease in the adolescent cohort that was studied 
and examines the utility of different screening methods – symptoms, household contact, the 
tuberculin skin test and the QuantiFERON TB Gold assay.  The sensitivity, specificity, positive 
predictive value and negative predictive values of these methods alone and in combination are 
reported. 
Contribution to the thesis and novelty 
This paper addresses the second objective of the thesis. Little data on the population prevalence 
of TB disease are available for adolescents. No data on the use of these different screening tools 
for detecting TB disease in adolescents were found. These data will be of use to those planning 
clinical trials of TB in adolescents and for TB programs considering screening interventions 
amongst adolescents. 
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Screening for tuberculosis (TB) disease is important for TB control and TB vaccine efficacy trials 
but this has not been evaluated in adolescents. We conducted a study to determine the 
prevalence of active TB and performance of specific screening tests for TB in adolescents in a 
high burden setting. Adolescents aged 12-18 years were recruited from high schools in a rural 
town in South Africa. Participants were screened for active TB using symptoms, household TB 
contact, positive interferon gamma release assay (IGRA) and positive tuberculin skin test (TST). 
Of 6363 adolescents recruited, 21 were newly diagnosed with TB of whom 19 were culture 
positive. After exclusions, the derived prevalence of smear positive TB was 16/5682 = 3/1000 
(95% confidence interval (CI) 1-4/ 1000). The sensitivity of TST and IGRA for active TB were 85% 
(95% CI 62-100%) and 94% (95% CI 79-100%) respectively. None of the methods alone or in 
combination had positive predictive values greater than 2%. The screening tools evaluated in 
this study may not be practical for routine use owing to low positive predictive values but may 
be useful in TB vaccine clinical trials. 


































Tuberculosis (TB) remains a significant public health problem globally.1 While TB Control 
Programmes have previously focused on optimal cure rates of smear positive TB patients, active 
case finding is receiving increased attention as an important component of strategies aimed at 
TB elimination. Early and improved case detection are both components of the Global Plan to 
Stop TB. 2, 3  In a different context, efficacy trials of new TB vaccines need effective methods to 
exclude cases of TB prior to study enrolment and to detect TB cases during follow up.   
 
Based on TB control programme data, age distributions of TB incidence show adolescence to be 
a period of increasing incidence. 4, 5 There are, however, no studies that have specifically 
investigated prevalence of active TB in adolescents.  Knowledge of prevalent TB in adolescents is 
relevant to public health programmes since these cases represent a source of transmission. 
Resulting new infections in turn present a high risk of progressing to active TB.6   
 
It has been shown that occurrence of TB in high burden settings is often due to exposure outside 
of the home environment. 7 Thus, adolescents may become infected in the school environment 
owing to the presence of active TB cases and may rapidly progress to active TB while still at 
school, representing a further risk to others. Early diagnosis in adolescents, who have been 
described as having a high “force of infection”, 8 is therefore important to reduce the risk of 
transmission in school settings where large numbers of adolescents congregate in closed spaces.  
 
Adolescents are also an important target group for TB vaccine trials.9 Knowledge of prevalence 
would assist with planning for TB vaccine trials since it is important to know the burden of TB for 
calculating trial sample sizes. 
 
The identification of prevalent cases requires effective screening tools. TB screening has been 
evaluated in communities in Africa, 10-12 amongst immigrants in a low burden setting 13 and 















in population-based surveys. 15 However, we have found no studies that have investigated TB 
screening specifically in adolescents. In the context of TB vaccine clinical trials, the value of good 
screening tools would be to exclude cases of TB at enrolment prior to vaccination for safety 
reasons and to detect TB cases during follow up as case ascertainment is crucial to the success 
of efficacy trials. Low cost, efficient screening tools are therefore needed to make trials as cost 
effective as possible.  
 
We thus conducted a study in adolescents to determine the prevalence of TB and the 
performance of various TB screening tools in detecting TB disease. As the routine use of the 
chest radiograph was not feasible in our setting, this was not included as a screening tool. Other 
publications on this study population include: 1) An examination of risk factors for latent TB 
infection based on the tuberculin skin test (TST) and QuantiFERON TB Gold (in-tube) (QFT) assay 
results at enrolment 16 2) A comparison of the predictive value of baseline TST and QFT for TB 
disease during follow-up 17 3) The determination of the predictive value of a QFT conversion for 
TB disease in a subset of participants who underwent extended follow up 18 and 4) TB incidence 
in an adolescent cohort in South Africa (manuscript under review).  
Methods 
Study setting: The study took place in the town of Worcester, approximately 100 kilometres 
from Cape Town, South Africa between July 2005 and April 2007.   
Study participants: All adolescents aged 12-18 years attending 11 high schools in the study area 
were approached to participate. 
Study procedures: At enrolment, demographic and clinical information (including history of 
current or prior household TB contact) was collected. Blood was taken for QuantiFERON® TB 
Gold In-tube (Cellestis, Victoria, Australia) (QFT) and a TST  was administered. Those with 
previous or current TB or with a previous severe reaction to a TST did not have a TST performed 
















The first 481 participants enrolled were all screened with a single sputum culture. For logistical 
reasons (the microbiology laboratory was not able to cope with a single sputum for culture on 
all study participants), the protocol was then amended to only screen the following: those with 
(1) TB symptoms (unexplained cough, night sweats, loss of weight or loss of appetite for two 
weeks or more, or haemoptysis), (2) a household contact within three years of enrolment, (3) a 
TST >10mm, or (4) a positive QFT. These participants were considered TB suspects and were 
investigated by the collection of two sputum samples for smears on two separate occasions. The 
sputum was concentrated and examined with a fluorescent stain (auramine). A positive smear 
was followed by a culture (liquid, Mycobacteria Growth Indicator Tube (MGIT, Bactec MGIT 960 
system, Beckton, Dickinson and Company, Franklin Lakes, New Jersey, USA) and solid, 
Loewenstein-Jensen) to confirm the presence of Mycobacterium tuberculosis, a chest 
radiograph and an HIV test.  
 
Definitions: TB disease was defined by at least two positive sputum smears and/or one positive 
sputum culture. However, data on all individuals placed on TB treatment by a physician were 
recorded.  
 
Data analysis: Data were captured in a Microsoft Access database, and analysed with STATA 
version 11.0 (Statacorp, Texas, USA). Data were verified and validated prior, during and after 
data entry according to a data entry standard operating procedure. Prevalence was calculated 
based only on the number of sputum smear positive cases diagnosed through study procedures 
excluding the first 481 who were screened with a single sputum culture. Sensitivities, 
specificities, positive predictive values and negative predictive values were calculated with 95% 
confidence intervals, using these prevalent cases as the reference standard. The screening tests 
were evaluated individually and in combination. Since recruitment was done in clusters (11 
schools), confidence intervals of rates and proportions were adjusted to take clustering into 
















Ethics: This study was approved by the Faculty of Health Sciences Human Research Ethics 
Committee of the University of Cape Town. Written informed consent was obtained from the 





6,363 adolescents aged 12-18 years were enrolled. This represented 58% of 10,492 registered 
learners at the high schools where recruitment took place. Enrolment rates by school ranged 
from 22.2% to 74.4% (31.8% in schools in affluent areas and 66.6% in schools in poorer areas. 
Schools in affluent areas made up 13.3% of the study population and 24.2% of the source 
population). The study population had a predominance of females of 54.3% (3458 participants). 
There were a greater proportion of younger adolescents (56.6% [3603] were <15 years of age) 
since there were fewer students in the higher than in the lower school grades. Figure 1 shows 
the TB related profile of the study population. Prevalence of latent TB infection based on both 
the TST (induration > 10 mm) and QFT, was present in 42.1% and 53.5% of the population 
respectively. There were 639 (10.0%) adolescents who reported having had TB before, while 
1728 (27.2%) had a current or prior household TB contact. Among the latter, 1055 (16.6%) had 
had a current or prior household contact within three years of enrolment.  Two hundred and 
one (3.1%) reported at least one TB related symptom at enrolment.  
Prevalence of TB 
The distribution and classification of cases is set out in Figure 2. In the cohort as a whole 
(N=6363), 21 adolescents were diagnosed with TB, of whom 17 were smear positive (all 
confirmed by culture), two were smear negative but culture positive (making up 19 culture 
positive cases in total), while two were diagnosed on clinical grounds. All 21 cases had 
pulmonary TB; none were classified as primary TB and no extra- pulmonary TB cases were 
diagnosed.  Both cases diagnosed on clinical grounds had chest radiographs compatible with TB 
disease. Amongst the culture positive cases, 15 out of 19 had abnormal chest radiographs 















Sixteen of the nineteen persons with culture confirmed TB agreed to HIV testing. Results were 
negative in all those tested.  Four of the 19 culture positive cases (21.1%) reported having had 
TB before. Of the 19 culture positive cases, 3 (one smear and culture positive and the two smear 
negative culture positive cases) were diagnosed amongst the first 481 participants on whom a 
single culture was automatically done (single culture group). Of the remainder (5882) who 
underwent step-wise screening (step-wise group), 3683 (63%) had at least one criterion for TB 
investigation (symptoms, recent household contact, positive TST or positive QFT). Of these, 3483 
(95%) were investigated with at least one smear amongst whom 16 cases of smear positive TB 
were diagnosed (all were confirmed by a positive culture). Those not investigated (200) were 
excluded from the analyses below. Thus, excluding the first 481 participants for whom screening 
procedures were different, we obtained a smear positive TB prevalence of 16/5682 (3/1000 
population, 95% CI 1-4/1000).  
Sensitivity, specificity, positive predictive value and negative predictive value 
The individual performance of each screening test is set out in Table 1. While sensitivities of the 
TST and QFT were high for TB disease, 84.6% (95% CI 61.9-100%) and 93.8% (95% CI 78.8-100%) 
respectively, sensitivities of “any symptoms” and recent household contact were very low, 
12.5% (95% CI 0.0-30.2%) and 31.3% (95% CI 0.0-63.9%) respectively. The reverse was true for 
specificity. Unexplained cough was the most common TB related symptom reported and the 
only one associated with diagnosed TB cases. Positive predictive values of all tests were all very 
low (< 2%) and negative predictive values very high (>99%). The lower number with data 
available for the TST as seen in Table 1 was due to those with prior or current TB not having had 
a TST done. If one assumed that those who did not have a TST done were TST positive, then 
sensitivity of the TST increased to 87.5% (95% CI 68.4-100.0%), specificity decreased to 51.9% 
(95% CI 42.3-61.4%) while positive predictive value and negative predictive value remained 
unchanged at 0.5% (95% CI 0.4-0.6%) and 99.9 (95% CI 99.8-100.0%) respectively. QFT has 
slightly less data available than the other screening tests due to QFT kits not being available at 
certain times or due to misbleeds i.e. not for any reason that might have introduced a bias. The 
performance of combined screening tools is outlined in Table 2. Sensitivity increased when 
combining screening tools and was above 85% when either a TST or QFT was part of the 
combination. The combination of either a positive TST or a positive QFT was 100% sensitive. 
















The first objective of the study was to measure the prevalence of TB disease amongst 
adolescents. We found a prevalence of smear positive TB of 3/1,000 amongst school-going 
adolescents in a high burden area in South Africa. In the British MRC trial of BCG which started 
in 1950 19, of 58,900 adolescents aged 14.5 to 15.5 years screened at study entry, 156 (3/1000) 
were found to have “definite” TB based on chest radiograph and chest clinic physician review. 
This 1950s British prevalence was similar to that found in our study, although case definitions 
differed. As we did not find any recent studies of TB prevalence amongst adolescents, the 
finding in our study is a useful benchmark for future studies of adolescents in high burden 
settings such as South Africa, especially given that screening took place in a modern TB control 
programme environment.  The World Health Organisation reported a global TB prevalence of 
2/1000 in 2011 and in the Africa Region as 3/1000.1 Since adolescence is a period of low but 
increasing TB disease, the prevalence figure reported for our study should be regarded as high 
for this age group.  
 
A Kenyan community based prevalence survey in a population aged >15 years, found a TB 
prevalence of 6.0/1000 based on smear or culture positive TB. 11 A prevalence study in high TB 
burden suburbs of Cape Town, South Africa, also in those aged >15 years, found a TB prevalence 
of 10/ 1000 based on smear or culture positive TB. 20 In our analyses, we used cases who were 
both smear and culture positive since sputum smear testing was the first step in our TB 
investigation algorithm and cultures were only done on those with positive smears. Also, there 
were none that were smear positive but culture negative. The DETECTB study in Zimbabwe 
found TB prevalences of 6.5/1000 and 3.7/ 1000 in adults before and after an intervention to 
reduce TB incidence and prevalence.12 The prevalences summarized above from studies 
conducted mainly in adults are not inconsistent with our findings since higher rates are expected 
in adults than in adolescents. However, comparisons have limited value given different TB 
burdens in different countries. 
 
The prevalent cases detected reflect a substantial proportion of untreated TB disease cases. This 















environment.  A substantial proportion of cases (>50% of smear positive cases) in the Cape 
Town study had had TB before. 20 This proportion was 21% in our study, more than double those 
reporting having had TB before (10%). This confirms previous TB as a risk factor for further 
episodes of TB.  
 
The high proportion of cases with normal chest x-rays (21%) was probably due to disease not 
being substantial enough to be visible on chest x-ray as a result of early detection. In children, 
positive cultures can be obtained with recent infection without disease on CXR – this certainly 
could also be a possibility in adolescents.  Five of the 19 adolescents with a positive culture had 
a household TB contact within three years of enrolment. Only one of these had an x-ray 
reported as normal. The less likely possibility is that there was laboratory contamination and 
that these positive cultures were false positive cases. Chest x-rays were done prior to treatment 
start and most (15 out of 19) were abnormal making “transient infection” or contamination an 
unlikely explanation in most cases. Also, we had a system of quality control which involved the 
use of dummy sputa and this process did not show laboratory contamination to be a concern.  
 
Case series describing the profile of adolescent TB have been published. 21-24 These series found 
primary TB and extra-pulmonary TB among their cases. However, they were mainly from 
hospital settings or across different age ranges in contrast with our own community based 
study.  
 
The second objective of this study was to examine the performance of different screening 
methods for TB disease. The World Health Organisation promotes three approaches to TB 
screening in population-based surveys : 15 1) Symptom and chest radiograph screening on all. 
Those with symptoms or abnormal chest radiographs are referred for a sputum smear and 
culture, 2) Symptom and chest radiograph screening, and sputa taken for smears on all. Cultures 
are only done if any of the former are positive, 3) Sputa are taken for smears and cultures on all. 
These range from the more affordable option, 1, to the more expensive option, 3. There is, 















require substantial laboratory capacity. Option 3 would not miss any case of pulmonary TB while 
options 1 and 2 would miss those cases not detected through their screening approach i.e. 
option 1 would miss smear or culture positive pulmonary TB cases without symptoms or chest 
radiograph abnormalities while option 2 would miss smear negative, culture positive cases 
without symptoms or chest radiograph abnormalities. These approaches were published after 
the completion of our study. 
 
We did not use chest radiographs in our study as the numbers recruited were too high to be 
radiographed at routine health care facilities in the area, and a specially purchased mobile 
radiograph facility was not financially feasible. We did, however, explore the use of measures of 
latent infection, the TST and QFT, and a history of a recent household contact in addition to 
symptom screening. While a positive QFT and TST were both sensitive indicators of prevalent TB 
alone, and 100% sensitive in combination, all screening methods, alone or in combination, had 
very low positive predictive values, suggesting that they would not be cost effective as case 
finding tools.  
 
The prevalence surveys in Cape Town and Kenya 10, 11 found chest radiographs to be sensitive 
screening tools for detecting TB, 94% and 97% respectively. Positive predictive values were not 
provided and we calculated them based on the data provided. The positive predictive value for 
any abnormal radiograph finding was 2% in the Kenyan study and 6% in the Cape Town study. 
We confirmed their fi dings that symptom screening has a low sensitivity for detecting TB 
disease. We speculate that adolescents may be reluctant to disclose TB symptoms, given that 14 
of the 16 smear and culture positive cases in our study did not report any symptoms. This aspect 
should be investigated in more depth in similar future studies of adolescents. 
 
The screening algorithm used in our study of collecting sputa for smears only on those with 
symptoms, a recent household contact, a positive TST or a positive QFT, reduced the proportion 
of the sample that needed sputum smears by about 40%. However, the fact that just over 60% 















effectiveness of the screening strategy we used. The prevalence of latent infection was higher 
than expected, reducing the value of TST and QFT as a screening tool. Given the low positive 
predictive values of the screening tools used in this study, it is clear that none of these screening 
methods would be effective in a routine health care setting i.e. many who test positive would 
have to submit sputum samples to find relatively few confirmed TB cases.  
 
Given the low background prevalence of TB, it may thus be difficult to find a cost-effective 
method of screening. In clinical trials, however, where there is an imperative both to exclude TB 
disease at baseline and to detect TB disease during follow up, there would be greater incentive 
to provide the costly resources needed for TB active case finding. A TST or QFT at least should be 
included as part of a screening strategy for adequate sensitivity. History of symptoms and/or 
household contact may be easily added to improve sensitivity. There is however a need to 
carefully discuss future disease endpoint definitions if symptomatic screening has poor sensitivity 
and measures of infection are too non-specific to be of value. 
 
Effective screening tools should meet certain criteria: 25, 26 the disease being screened for should 
be important and treatable; there should be a recognizable latent or early symptomatic phase; 
and a suitable acceptable test should be available which is cost-effective. While high sensitivity 
is an important characteristic of a good screening tool, positive predictive value is relevant to 
determine operational feasibility and cost effectiveness. TB meets the criteria for a disease 
amenable to screening  25, 26 since it is a common and serious disease and is treatable. On the 
other hand, the prevalence is relatively low and the effective screening tools available have low 
positive predictive values and are therefore unlikely to be cost-effective. Besides the costs of 
diagnostic tests themselves, one should take into account transport of specimens (sputum 
screening), repeated visits (TST), laboratory infrastructure (sputa, QFT) and personnel required. 
Cost effectiveness analyses in other contexts have shown various outcomes. A single post travel 
TST was most cost effective for TB screening for Canadians returning from travel abroad 27 but 
chest radiographs were more cost effective when screening immigrants from high burden 
countries. 28 A chest radiograph in Kenya was more cost-effective than a sputum smear in 















screening all HIV negative adults with TB symptoms and all HIV positive persons in a high TB and 
HIV burden area for TB disease was found to be feasible and cost-effective. 30 Given these 
results from other studies, a formal cost-effectiveness analysis of TB screening in adolescents 
may be necessary before any final conclusions are drawn about the cost effectiveness of 
screening for TB in adolescents. 
Limitations 
This study was focused on school going children as a feasible target group for vaccination rather 
than the whole community. Adolescents who had dropped out of school would probably be at 
higher risk of TB and this study is likely to have underestimated the true prevalence of TB in the 
adolescent population as a whole. Refusals were dictated mainly by fear of blood draws, so we 
do not believe that the included population is substantially different from those who declined to 
participate. We were dependent on adolescents reporting symptoms and household contacts 
and these may not have been accurately reported. As cultures were done mainly to confirm 
smear positive TB, our TB prevalence is an underestimate of the actual prevalence of culture 
positive TB. Another source of potential under- or overestimation was that 7% of participants 
who met the criteria for investigation did not undergo sputum testing. Variations in recruitment 
rate by school might have biased these results as well. Since schools in affluent areas were less 
well represented, these results probably overestimate the true prevalence of TB. However, we 
think that this was to a limited extent given the proportions of school-going adolescents 
attending schools in affluent areas. The impact of those not having TSTs due to having prior or 
current TB was tested by assuming that these would be TST positive. We found that sensitivity 
increased by 3% which we felt was relatively small. 
Conclusion 
This study in a high burden setting found a TB prevalence of 3/ 1000 but the screening methods 
used all had low positive predictive values. They may thus not be feasible for use in a routine 
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TB profile of the adolescent population (%) (n=6363). 
TB – tuberculosis. 
TST – tuberculin skin test. 
TST positive – induration of 10 mm or more. 













Prior TB TB contact
within last
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screened with sputum 
culture: 481 
Number smear and 
culture positive cases: 1 
Number smear negative 




Number indicated for 
investigation: 3683 
Number investigated 
with at least one 
sputum smear: 3483 
Number smear  and 
culture positive cases: 
16 
Number smear negative 
culture positive cases: 0 
Excluded from analysis 















Table 1: Sensitivity, specificity, positive predictive value and negative predictive value of 
screening tests for smear and culture positive TB diseasea  






















































































































































CI – confidence interval, PPV – positive predictive value, NPV – negative predictive value. 
 















Table 2: Sensitivity, specificity, positive predictive value and negative predictive value of 
combinations of screening tests for smear and culture positive TB diseasea 
 
 




  TB cases 
detected 












Any TB symptom or recent household TB contact only 
Any TB symptom or household contact 















Any TB symptom + either TST or QFT 




























Recent household TB contact + either TST or QFT 
Household contact within 3 years or a 














































Any TB symptom, a household contact 















Any TB symptom, a household contact 















CI – confidence interval, PPV – positive predictive value, NPV – negative predictive value.  
















Chapter 5: TB incidence in an adolescent cohort in South Africa 
 
Paper overview 
This analysis reports on the incidence of TB disease in the adolescent cohort that was studied 
and the risk factors at baseline that were predictive of TB disease onset within 2- 4 years.  A 
multivariate analysis using a Cox regression was used to determine these factors. The profile of 
cases and incidence rates using different case definitions are also reported. 
Contribution to the thesis and novelty 
This paper addresses the third objective of the thesis. Little data on the population incidence of 
TB disease are available for adolescents. No previous data on the factors predicting TB disease in 
adolescents were found. These data will be of use to those planning clinical trials of TB in 
adolescents especially with respect to estimating sample sizes and designing case definitions. 
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Tuberculosis (TB) is a major public health problem globally. Little is known about TB incidence in 
adolescents who are a proposed target group for new TB vaccines. We conducted a study to 
determine the TB incidence rates and risk factors for TB disease in a cohort of school-going 
adolescents in a high TB burden area in South Africa. 
Methods:  
We recruited adolescents aged 12 to 18 years from high schools in Worcester, South Africa. 
Demographic and clinical information was collected, a tuberculin skin test (TST) performed and 
blood drawn for a QuantiFERON TB Gold assay at baseline. Screening for TB cases occurred at 
follow up visits and by surveillance of registers at public sector TB clinics over a period of up to 
3.8 years after enrolment.  
Results   
A total of 6,363 adolescents were enrolled (58% of the school population targeted). During 
follow up, 67 cases of bacteriologically confirmed TB were detected giving an overall incidence 
rate of 0.45 per 100 person years (95% confidence interval 0.29-0.72). Black or mixed race, 
maternal education of primary school or less or unknown, a positive baseline QuantiFERON 
assay and a positive baseline TST were significant predictors of TB disease on adjusted analysis.  
Conclusion 
The adolescent TB incidence found in a high burden setting will help TB vaccine developers plan 
clinical trials in this population. Latent TB infection and low socio-economic status were 
predictors of TB disease. 
















Tuberculosis (TB) is a major public health problem globally with 8.8 million cases being 
diagnosed in 2010 of whom 1.1 million died who were HIV negative and 0.35 million who were 
HIV positive [1]. Incidence rates start to rise in adolescents and precede a peak in adulthood in 
developing countries [2]. New TB vaccines are being developed as part of the strategy to combat 
TB and adolescents are a proposed target for such vaccines [3]. However, relatively little has 
been published on the incidence of TB in adolescents. Two clinical trials of BCG in adolescents 
provide limited incidence data [4,5] and studies on TB in adolescents have focused on the 
clinical features of TB in this group [6-9]. A latent TB infection prevalence of about 50% has been 
reported for the population described in this report and for another adolescent group from 
South Africa [10,11].  
 
Since there is currently no immune correlate of protection against TB, end points based on 
evidence of TB disease will be needed for new TB vaccine efficacy trials and these would need to 
be specific to optimize efficacy assessments [12,13]. Knowledge of TB incidence rates based on 
specific clinical disease features will be crucial for planning the size of efficacy trials.  
 
We conducted a study to determine the TB incidence rate and risk factors for TB disease in a 
cohort of school-going adolescents in a high TB burden area in South Africa. Other publications 
on this study population include: 1) An examination of risk factors for latent TB infection based 
on the tuberculin skin test (TST) and QuantiFERON TB Gold (in-tube) (QFT) assay results at 
enrolment [11] 2) A comparison of the predictive value of  baseline TST and QFT for TB disease 















disease in a subset of participants who underwent extended follow up [15] and 4) The 
measurement of the prevalence of TB disease at enrolment and the value of certain screening 
tests for detecting TB (manuscript under review).  
Materials and Methods:  
Study setting: The study took place in the town of Worcester and surrounding villages, 
approximately 100 kilometres from Cape Town, South Africa.  The total population of the 
municipal area from which the adolescents were drawn was estimated as 146,101 by the 
Department of Health in 2005, the year when recruitment started. According to the national 
Census of 2001, there were 21,056 adolescents aged 12-18 (14% of the total population) in the 
municipal area targeted and 83% of these adolescents were attending schools. The study area 
was a subset of the municipal area and consisted of a major town and two villages within this 
area. Based on the Census 2001 population data for the municipal area and high school 
attendance data of 10,492 in the study area, we estimated that there were 12,641 adolescents 
aged 12-18 years in the study area in total. 
Study participants: All adolescents aged 12-18 years attending all 11 publicly funded high 
schools in the study area were approached to participate. The very few small private schools in 
the study area were not approached. 
Study procedures: At enrolment, demographic, socio-economic and clinical information were 
collected through interview of parents and the participating adolescent [11]. Blood was taken 
for QuantiFERON® TB Gold In-tube (Cellestis, Victoria, Australia) (QFT) and a TST  was 
administered at baseline. Those with previous or current TB or with a previous severe reaction 
to TST did not have a TST performed, in order to prevent severe allergic reactions. The reading 















more commonly used limit of 72 hours but there are data and recommendations which suggest 
that this is acceptable [16,17]. A trained nurse examined each adolescent for a BCG scar. 
Participants were screened for TB at baseline (the overall number of cases diagnosed will be 
reported here but details of these cases are the subject of another publication (4 above)). 
 
All participants enrolled were scheduled for follow up visits after two years which included a 
blood draw for QFT and the administration of a TST. About half underwent three monthly visits 
prior to this which included six monthly QFTs and annual TSTs to compare follow up strategies 
while the other half were seen only at baseline and two year visit (details of the comparison of 
the two follow up strategies will be reported separately). At follow up visits, those with new 
symptoms or a new household contact compared to baseline, a converted TST (>10 mm increase 
from baseline) or converted QFT (change from negative to positive) were investigated for TB 
disease. In addition, passive surveillance was conducted of TB clinic and hospital admission 
registers in the area for any TB cases diagnosed between visits.  Investigation for TB involved the 
collection of two sputum samples for smear examination on two separate occasions. For 
persons with at least one positive smear, a culture was performed, a chest x-ray done and an 
HIV test offered. The radiologist’s report on the chest x-ray was used to classify chest x-ray 
findings.  
Study duration: Enrolment started in July 2005 and was completed in April 2007. Follow up was 
completed at the end of February 2009. Owing to financial constraints, about 10% of the two 
year visits were performed one to two months short of two years towards the end of the study. 















visits were followed up passively until all other subjects had completed their two year visits. This 
gave a maximum follow up time of 3.8 years.   
Definitions: 
The protocol definition of a TB case was a diagnosis of intrathoracic TB with either two positive 
sputum smears and/ or one single positive sputum culture (“bacteriologically confirmed TB”). 
However, data on all individuals placed on TB treatment by a physician were recorded (“all TB”). 
A chest x-ray consistent with active TB was defined as “compatible with TB” - this included 
pleural effusions. An “abnormal chest x-ray” was defined as any abnormality judged to be 
evidence of active disease including TB and evidence of old/ previous disease.  
Sample size determination 
Those agreeing to participate determined the sample size. Based on routine TB programme 
data, we expected to find an incidence rate of bacteriologically confirmed TB of 0.5 per 100 
person years.  With an anticipated sample size of 6,500 and an expected incidence rate of 
bacteriologically confirmed TB of 0.5 per 100 person years over two years of follow up, we 
expected to yield a 95% confidence interval (precision) of approximately 0.4 to 0.6 /100 person 
years.   
Data analysis and statistical considerations: 
Data were captured in a Microsoft Access database, and analysed with STATA version 11.0 
(Statacorp, Texas, USA). Data were verified and validated prior, during and after data entry 
















Total person-time for TB incidence analysis was calculated from date of enrolment to date of the 
last visit of the last participant, TB diagnosis or death, whichever occurred first. Those lost to 
follow-up were assigned the duration of time to when last seen plus half the duration between 
that visit and the next missed visit. Univariate analysis was performed on demographic, socio-
economic and clinical characteristics examining their association with “bacteriologically 
confirmed TB”. Hazard rates with 95% confidence intervals were calculated using Poisson 
regression. The design effect was accounted for during statistical analysis, the clusters being the 
11 schools from which the participants were enrolled. Kappa statistics were used to evaluate 
collinearity amongst the potential risk factor variables to avoid over-matching in building models 
for multivariate analysis. The risk factors for TB disease were analysed in a multivariate Cox 
regression model using the statistically significant variables (p < 0.05) on univariate analysis to 
determine adjusted hazard ratios.  
Ethics: This study was approved by the Faculty of Health Sciences Human Research Ethics 
Committee of the University of Cape Town. Written informed consent was obtained from the 
parents of adolescents and assent obtained from adolescents. 
Results   
6,363 adolescents were enrolled (58% of 10,492 registered at local schools and 50% of the 
estimated total adolescent population of 12,641 in the study area). Enrolment by school ranged 
from 22.2% to 74.4%. 5203 (81.8%)  participants completed their two year visits, 660 (10.4%) 
withdrew, 11 (0.2%) died and 489 (7.7%) were lost to follow up prior to their two year visit. 84% 
















Participant baseline profile 
The demographic and clinical profile of participants at enrolment is shown in Table 1. There was 
a slight predominance of females (54%) in the study population compared to the source 
population data supplied by the Department of Education (50% were female). There was a 
greater proportion of younger adolescents (<15 years) than those >15 years since there were 
fewer adolescents in the higher school grades. BCG scars were faded in some adolescents so it 
was difficult to be sure about their presence in certain instances. Twenty one cases of TB were 
diagnosed at baseline of whom 19 were culture positive. 
Profile of incident cases 
There were 87 TB incident cases detected during follow up, 67 (77.0%) of whom met the 
protocol definition (bacteriologically confirmed TB). A profile of the cases is set out in Table 2. 
Please note that 7 non- 
tuberculous mycobacteria (NTMs) were cultured at baseline and 2 during follow up. Most 
incident cases (61 or 70%) were culture positive and most (63 or 72%) had chest x-ray changes 
suggestive of TB. All those diagnosed with TB (87) were offered HIV testing, 61 (70.1%) of whom 
accepted and of whom only one (1.6%) was found to be positive. 
Incidence rates 
Incidence rates using varying definitions of what constitutes a TB case are set out in Table 3. This 
resulted in a range of incidence rates from 0.30 to 0.59/ 100 person years. The highest annual 
number of cases occurred during the second year of follow up i.e. 33 (49%) of bacteriologically 
confirmed cases (Table 4). Ten additional cases (15%) were detected through surveillance after 
the two year visit. The rates of disease in the successive years of follow up were not statistically 















schools from 0 to 2% cumulative incidence and 0 to 0.9/100 person years incidence rates 
suggesting the possibility of micro-epidemics in certain schools but confidence intervals were 
wide making these data difficult to interpret. Eight bacteriologically confirmed cases were 
diagnosed within 6 months of enrolment. If we consider the possibility that these may have 
been cases missed at baseline and were in fact prevalent cases, then the incidence rate based 
on the bacteriologically confirmed cases drops to 0.40 per 100 person years (pyrs) (95% CI 0.27-
0.58). Incidence rates by TST induration size were as follows: <5 mm - 0.20/100 pyrs (95% CI 
0.11-0.38), 5-9 mm - 0.17/100 pyrs (95%CI 0.04-0.71), 10-14 mm - 0.40/100 pyrs (95% CI 0.30-
0.53) and >15 mm - 1.18/100 pyrs (95% CI 0.77-1.81). There was thus a trend of increasing 
incidence with increasing induration with an induration of >15 mm being significantly higher 
than the other categories. 
Risk factors for TB 
An unadjusted univariate analysis of the relationship between demographic, socio-economic 
and clinical variables, and TB incidence using hazard ratios is set out in Table 1.  A comparison 
between those having three monthly follow up versus those with just a baseline and two year 
visit showed no statistically significant difference in incidence rates and is not shown in this 
analysis. In unadjusted analysis, statistically significant risk factors for bacteriologically 
confirmed TB were being of black or mixed race origin compared to being of white or Indian 
origin, maternal education primary school or less and  maternal education unknown, current or 
prior household contact, a positive TST and a positive QFT. Absence of a BCG scar was of 
borderline statistical significance. These risk factors were considered for fitting in a Cox 
regression model. We could not include ethnic group since there were no cases in the reference 
group. Maternal education primary school or less and maternal education unknown were 















therefore assumed that those with an “unknown/ unsure” scar were BCG vaccinated and these 
were grouped with those with a definite scar present for the Cox regression analysis. The 
following comparisons were tested for collinearity using the kappa statistic: TST versus QFT, 
prior or current household TB contact versus TST and prior or current household TB contact 
versus QFT since all three were potential indicators of TB exposure. Only the TST and QFT 
outcomes were found to be collinear (percentage agreement 85.0%, kappa 0.7). They could thus 
not be fitted into a model simultaneously. In adjusted analysis (Table 5), absence of a BCG scar, 
maternal education primary school or less, or unknown and a positive QFT were statistically 
significant predictors of TB disease while prior household contact was not.  When QFT was 
replaced with TST in the model (not shown), the TST was also a significant predictor with a 
hazard ratio of 2.4 (95% CI 1.2-4.8). In this model, maternal education primary school or less or 
unknown remained a predictor of TB disease (hazard ratio 1.9, 95% CI 1.1-3.1) but not absence 
of a BCG scar. When we defined the presence of a BCG scar strictly and excluded those with scar 
“unknown/ not sure” and repeated the Cox regression (N = 4061), BCG scar and QFT were both 
only of borderline significance, hazard ratios 1.7 (95% CI 0.9 - 3.2, p=0.06) and 1.7 (95% CI 1.0-
2.9, p=0.07) respectively while maternal education of primary school or less or unknown 
remained significant at hazard ratio 1.4 (95% CI 1.0-1.9, p=0.04). With this reduced dataset, 
when TST replaced QFT in the model, only TST remained significant 2.4 (95%CI 1.3-4.3, p=0.007). 
Discussion 
We found a bacteriologically confirmed TB incidence rate of 0.45/100 person years of TB in 
school-going adolescents in a high burden area. Taking this incidence of 0.45/100 person years 
and the prevalence of 3/1000 or 0.3/100 reported in chapter 4 and using the formula of 
incidence = prevalence X duration, this amounts to an average duration of prevalent TB of 1.5 















bacteriologically and most had evidence of chest x-ray abnormalities. Significant predictors of TB 
disease during follow up included demographic, socio-economic and latent TB infection 
variables. While it was notable that most incident cases occurred in the second year of follow 
up, differences across the years were not statistically significant. 
 
The British MRC trial in adolescents aged 14.5-15.5 years conducted from 1950-1970 showed an 
annual incidence rate of 0.25 per 100 in the first five years of the study in the BCG unvaccinated 
group who were TST negative at enrolment with a similar rate in those with a TST of >15mm at 
enrolment [5]. This rate was similar to the 0.2 per 100 found in the TST negative group in our 
study but not to those with an induration of >15 mm who had a significantly higher incidence 
rate than those with a negative TST. One important difference was that the adolescents in our 
study had mostly been vaccinated with BCG at birth. Those who were BCG vaccinated in the 
MRC trial had a lower rate of 0.04 per 100 but had been vaccinated in adolescence as part of the 
trial so cannot be compared to the adolescents in our study. Children who were aged 7-14 years 
of age in the Brazilian BCG revaccination trial had rates of 0.03 per 100 person years [4], much 
lower than in our study. This is probably due to the difference in burden of TB in each country 
given that South Africa (981/100,000) has a much higher overall incidence rate of TB than Brazil 
(85/100,000) (2010) [1]. The TB incidence rate found in this study is similar to that based on 
routine TB control programme data in our study area. It was also similar but not identical to the 
rate reported in a prior publication on this cohort (0.43/100 person years) due to that analysis 
focusing on a subset of the cohort (5244) where participants with both baseline TST and QFT 
















The profile of cases in our study was typical of adult type disease, a finding similar to that shown 
in a different adolescent population in South Africa by Weber et al [6]. They reviewed the TB 
diagnosis records of 324 adolescents aged 10-18 years and found 78% to have had 
bacteriological evidence of disease and 94%, intra-thoracic lesions on chest x-ray. They found 
10% with evidence of primary TB whereas we found none, but their lower age limit was younger 
(10 years) than in our study (12 years).  Very few extra-thoracic cases of TB were detected in our 
study similar to the 6% of cases reported as extra-thoracic by Weber et al [6]. At least 87% of 
cases in our study had abnormal chest x-rays confirming the microbiological findings of evidence 
of TB disease.  
 
The choice of TB case definition resulted in some variation in the TB incidence calculation. Given 
the need for a specific definition in a clinical trial setting to avoid undermining efficacy estimates 
[12,13], careful consideration needs to be given to the endpoint case definition for clinical trials.  
Unlike the pediatric setting where the disease is pauci-bacillary and where reaching consensus 
on endpoints for infant trials has been difficult [18], most cases in adolescents were 
microbiologically confirmed suggesting that the use of a highly specific definition is feasible.  
 
We have shown previously that latent TB infection as demonstrated by a positive TST or QFT is 
associated with a higher risk of progressing to TB disease [14]. The analysis in this paper shows 
specifically that this relationship persists even when confounders are controlled for. The 
treatment of latent TB infection with isoniazid as prophylaxis (IPT) is not standard of care in 
South Africa for HIV negative persons over the age of 5. Fifty percent of adolescents as shown in 















South Africa would thus be very resource intensive. The benefits of IPT in high TB burden 
settings for HIV negative adolescents and adults are not clear. A recent large study of IPT in 
miners in South Africa showed benefit in reducing the risk of TB only while isoniazid was being 
taken but this benefit was lost when treatment was completed [20]. The university ethics 
committee which approved this study did not require the provision of INH prophylaxis in 
adolescents who were latently infected. 
 
The fact that the absence of a BCG scar was shown to be linked to a higher risk of developing TB 
is surprising given the high population burden of TB in a country with a high coverage of BCG 
(>95%) [21]. The benefit was only found when QFT was part of the multivariate model but not 
when it was replaced with TST nor when the presence of the BCG scar was strictly classified and 
those whose scars were classified as “unsure” were excluded from analysis. There should 
therefore be caution in interpreting this finding and the absence of a BCG scar may not be 
indicative of an absent immune response to BCG or indicative of not receiving BCG. A study in 
India showed no difference in leukocyte migration levels in young BCG vaccinated children 
between those who developed a BCG scar and those who did not [22]. A recent editorial 
referencing this and other studies also commented on the lack of correlation between adaptive 
cellular immune responses and BCG scar formation, and the authors recommend further studies 
to clarify the differences between those with and those without a BCG scar [23]. 
 
The fact that a low or unknown level of maternal education is linked to progression to TB 
disease is interesting and requires further investigation but surprisingly, parental low income 















that household TB contact was not shown to be a statistically significant risk factor for TB on 
adjusted analysis. This may be because the study was not sufficiently powered to show this 
relationship or due to household contact being very common in this high burden setting. Black 
or mixed race was a perfect predictor of the onset of TB.  It is likely that this association is linked 
to underlying socio-economic factors given South Africa’s history [24] but this could not be 
properly tested in multivariate analysis. 
 
The TB incidence rates measured in this study show that large sample sizes will be needed to 
power clinical trials evaluating the efficacy of new TB vaccines in adolescents. For a vaccine trial 
expected to show a vaccine efficacy of 60% at a 95% significance level and with 80% power, a 
study duration of 2 years with completion rate of 82% and cumulative incidence of 
bacteriologically confirmed TB of 1.05% in the unvaccinated group (as found in this study [Table 
3]), a sample size of 6400 participants would be needed in a study with a 1:1 vaccine to placebo 
ratio. Since pre and post infection TB vaccines are being developed, sample sizes for trials would 
have to be calculated separately for those latently uninfected and those latently infected. This is 
further addressed in more detail in chapter 8. 
 
This study has a number of limitations: HIV testing was not done routinely because it was 
believed that this population would not have a high prevalence of HIV. This decision was 
vindicated by the finding that among participants diagnosed with TB, only one was confirmed to 
be HIV positive with most agreeing to be tested. Besides the data on gender distribution, no 
other data was available on those not enrolled in the study. A proportion was older than 18 but 















draws. Our results may thus be biased because of differences between the enrolled and 
unenrolled populations but we do not believe that this was major given the main reason given 
for refusal to participate and given that others were not eligible due to their age.  
 
The selections of schools as the source of participants introduced a cluster effect and this 
produced incidence rates with wider confidence intervals than would have been produced by a 
purely random sample. While the majority of participants who met the criteria for investigation 
for TB underwent the required tests, some (371) did not which may have resulted in the actual 
number of cases being underestimated. However, we believe that the surveillance system would 
in most instances have eventually  picked up cases missed in this way. Hypothetically, given a 
cumulative incidence of 1.05%, 4 TB cases could have been missed in this group. Smear 
negative, culture positive TB cases diagnosed early in year one might possibly be cases missed at 
baseline given that smears were the main method of investigation. In a clinical trial setting using 
more rigorous screening methods, such cases would have been picked up at baseline and the 
rates in this study may therefore be an overestimate of incidence relative to what might be 
expected in a clinical trial. An endpoint committee was not used for case classifications. The case 
classifications were purely data driven with chest x-ray findings being based only on the 
radiologists reports. Given that most data items were clear-cut, we do not believe that an 
endpoint committee would have classified cases significantly differently.  
 
Finally, this study represents the burden of disease at schools only. Adolescents not at school 
are likely to be located in poorer environments and the TB incidence rate in the total population 
















In conclusion, the incidence rates in school-going adolescents in a high burden TB setting ranged 
from 0.30 to 0.59 per 100 person years using varying case definitions. These data will be 
essential for the planning of clinical trials of new TB vaccines in adolescents. The risk factors 
shown to be associated with TB will be useful in estimating TB rates in various risk groups in 
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 Table 1: Unadjusted analysis of risk factors for TB disease for bacteriologically 
confirmed TB cases. 











Gender       
Female 3,458 (54.3%) 45 0.55 1.7 0.5-5.3 
Male (ref***) 2,905 (45.7%) 22 0.33 1.0 - 
Age (years)       
>15 2,760 (43.4%) 31 0.49 1.2 0.7-2.0 
<15 (ref) 3,603 (56.6%) 36 0.42 1.0 - 
Racial group       
Black and mixed race  5,921 (93.1%) 67 0.48 Perfect predictor 
Indian/ white (ref) 442 (6.9%) 0 0.00    
Parent income:  classified on at least one parent’s income    
<R4000 /month  5,313 (83.5%) 62 0.50 2.3 0.6-8.7 
>R4000 /month (ref)  1,050 (16.5%) 5 0.22 1.0 - 
Maternal highest education level  















High school or more (ref) 3,482 (54.7%) 24 0.29 1.0 - 
Unknown 988 (15.5%) 15 0.68 1.6 1.1-2.4 
Paternal highest education level  
Primary school or less 849 (13.3%) 12 0.59 1.4 0.6-3.0 
High school or more(ref) 2,042 (32.1%) 15 0.31 1.0 - 
Unknown:  3,472 (54.6%) 40 0.50 1.3 0.8-2.0 
BCG scar       
Absent 1,813 (28.5%) 24 0.59 1.5 1.0-2.2 
Present (ref) 2,565 (40.3%) 22 0.36 1.0 - 
Unknown (Not sure)  1,985 (31.2%) 21 0.46 1.0 0.6-1.6 
Current or prior TB household contact   
Yes  1,728 (27.2%) 31 0.77 2.3 1.1-4.8 
No (ref) 4,635 (72.8%) 36 0.45 1.0 - 
Previous TB       
Yes 639 (10.0%) 7 0.481 1.5 0.7-3.2 
No (ref)  5,709 (89.7%) 60 0.45 1.0 - 
Unknown 15 (0.3%) 0 0.00 0  















TST positive (>5 mm) 3,115 (49.0%) 44 0.61 3.0 1.4-6.5 
TST negative (ref) 2,456 (38.6%) 12 0.20 1.0 - 
TST unknown**** 702 (12.4%) 11 0.68 1.6 0.7-3.7 
QFT status at baseline      
QFT positive 3,233 (50.8%) 48 0.65 2.4 1.4-4.2 
QFT Negative (ref) 2,804 (44.1%) 17 0.27 1.0 - 
QFT indeterminate or 
unknown 
326 (5.1%) 2 0.21 0.5 0.05-4.7 
*pyrs – person years 
**95% CI = 95% confidence interval 
#adjusted for the design effect 
***ref – reference 
****  Those with previous or current TB or with a previous severe reaction to TST did not have a 
















Table 2: Profile of TB incident cases 







Number of cases Total 87 (100%) 67 (100%) 
Site of disease Intrathoracic 
Extra-thoracic 
84 (97%) 
3 (  3%) 
67 (100%) 




Smear and culture positive 
Smear negative, culture positive 
Smear positive, culture negative 
Smear and culture negative 
Smear positive, culture not done 





2 (  2%) 




0 (  0%) 
2 (  3%) 
0 (  0%)  
Chest x-rays 
 
Compatible with TB: 
Abnormal but not typical of TB 
Compatible with old/ healed TB 
63 (72%) 
8 (  9%) 
5 (  6%) 
51 (76%) 
6 (  9%) 
















Not done/ missing/ no report 
3 ( 3%) 
8 (  9%) 
1 (  1%) 




















Table 3: TB incidence rates using different case definitions. 
 Cases Cumulative 
incidence (%) 
(Mean 2.3 years of 
follow up) 
 N= 6,363 
Incidence rate (per 
100 pyrs*)  
(95% CI**)***. 
pyrs = 14,786 
All 87 1.36 0.59 (0.36-0.96) 
Bacteriologically confirmed 67 1.05 0.45 (0.29-0.72) 
Culture confirmed  61 0.96 0.41 (0.23-0.71) 
Chest x-ray compatible with TB 63 0.99 0.43 (0.27-0.68) 
Culture positive and chest x-ray 
compatible with TB 
45 0.71 0.30 (0.17-0.54) 
Culture positive and abnormal 
chest x-ray (includes those 
compatible with TB) 
54 0.85 0.37 (0.21-0.62) 
Bacteriologically confirmed TB and 
chest x-ray compatible with TB 
51 0.80 0.34 (0.21-0.56) 
Bacteriologically confirmed TB and 
abnormal chest x-ray 
61 0.96 0.41 (0.27-0.64) 















**95% CI = 95% confidence interval 
















Table 4: Annual incidence rate by year of study up to February 2009 for bacteriologically 
confirmed TB* (n=6,363) 
 
 Year Persons Cases Pyrs 
Incidence rate (per 
100 pyrs**)  
 (95% CI***)**** 
Yr 1 6363 23 6,245 0.37 (0.19-0.72) 
Yr 2 5784 33 5,557 0.59 (0.40-0.88) 
Yr 3 4884 11 2,762 0.40 (0.21-0.75) 
Total   67 14,786 
0.45 (0.29-0.72) 
 
*No cases were reported in year 4 of follow up so this rate has not been included in the table. 
**pyrs = person years 
***95% CI = 95% confidence interval 





















Ratio P > z 95% CI*# 
    BCG scar absent 1.5 0.04 (1.0-2.1) 
Positive baseline QuantiFERON 2.0 0.02 (1.2-3.3) 
Mother’s education primary school or less, 
or unknown 
1.8 0.01 (1.2-2.7) 
Prior or current household TB contact 1.7 0.15 (0.8-3.9) 
*95% CI = 95% confidence interval 
















Chapter 6: The tuberculin skin test versus QuantiFERON TB Gold(R) in 




This analysis reports on the predictive value of a tuberculin skin test compared to a commercial 
interferon gamma release assay as measured at baseline for TB disease in the adolescent 
cohort. The data from this study are compared to other studies assessing predictive value 
Contribution to the thesis and novelty 
This paper addresses the fourth objective of the thesis. Little data on the predictive value of 
interferon gamma release assays compared to the tuberculin skin test for TB disease (and even 
less for high TB burden settings) were available at the time of this study. These data has been 
utilised in two systematic reviews and for guideline development on interferon gamma release 
assays by the Centers for Disease Control (CDC), Atlanta, USA and the World Health 
Organisation. 
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Setting: This study was conducted in a high tuberculosis (TB) burden area in Worcester, South 
Africa, with a notified all TB incidence rate of 1,400 /100,000.  
 
Main objective: To compare the predictive value of a baseline tuberculin skin test (TST) with that 
of the QuantiFERON TB Gold (In-tube) assay (QFT) for subsequent microbiologically confirmed 
TB disease among adolescents.  
 
Methods: Adolescents aged 12-18 years were recruited from high schools in the study area. At 
baseline, blood was drawn for QFT and a TST administered. Participants were followed up for up 
to 3.8 years for incident TB disease (median 2.4 years). 
 
Results: After exclusions, 5244 (82.4%) of 6,363 adolescents enrolled, were analysed. The TB 
incidence rate was 0.60 cases per 100 person years (pyrs) (95% CI 0.43-0.82) for baseline TST 
positive (> 5 mm) participants and 0.64 cases per 100 pyrs (95% CI 0.45-0.87) for baseline QFT 
positive participants. TB incidence rates were 0.22 per 100 pyrs (0.11-0.39) and 0.22 per 100 
pyrs (0.12-0.38) among those with a negative baseline TST and QFT respectively. Sensitivity for 
incident TB disease was 76.9% for TST and 75.0% for QFT (p=0.81). Positive predictive value was 
















Conclusion: Positive TST and QFT tests were moderately sensitive predictors of progression to 
microbiologically confirmed TB disease.  There was no significant difference in the predictive 
ability of these tests for TB disease amongst adolescents in this high burden setting. Therefore, 
these findings do not support use of QFT in preference to TST to predict the risk of TB disease in 
















Latent tuberculosis (TB) infection has historically been diagnosed with a tuberculin skin test 
(TST). However, with this method, cross reactivity with BCG and non tuberculous mycobacteria 
(NTMs) undermines the specificity of the test[1]. As an alternative to the TST, interferon γ 
release assays (IGRAs) have been developed which utilise antigens not present in BCG and most 
NTMs[2]. The advantages of these assays over TSTs are: a second visit for reading of the test is 
no longer necessary; boosting due to repeated testing is avoided; they have greater specificity 
for latent TB infection; and they are less prone to the biases encountered when measuring the 
size of skin reactions, such as digit preference[3]. However, IGRAs are more expensive, need a 
blood draw and require a sophisticated laboratory.  
 
The QuantiFERON TB Gold (In-tube method) (Cellestis Limited, Carnegie, Victoria, Australia) 
(QFT) is one such commercially available assay which has been adopted by many countries as an 
alternative to TST or as part of a two step approach which uses both tests – a TST is done first 
and those with a positive test result, have a QFT done. QFT uses ESAT-6, CFP10 and antigen 7.7 
of Mycobacterium tuberculosis as stimuli to determine if T cells in whole blood are sensitized to 
such antigens thus indicating prior exposure and/ or evidence of latent TB infection. 
 
The predictive value of a positive TST for TB disease has been shown in isoniazid prevention 
trials and contact investigations[4,5,6].   When our study was initiated,  there was a call to 
conduct longitudinal studies with the new assays so as to determine their validity in predicting 
TB disease[7,8]. Some longitudinal studies have been done to date but the results have been 















others show no difference between them[9,10,11,12,13,14,15]. References 9 and 14 concluded 
that IGRAs had superior prognostic ability for TB over the TST whereas references 10-13 and 15 
did not. Most of these studies were designed as follow up of contacts of cases diagnosed with 
TB so it is not clear what the relative value of these tests would be in a general population 
setting.  
 
We conducted a longitudinal study to determine the predictive value for subsequent TB disease 
of QFT compared to TST in a large cohort of adolescents in a high burden setting. The baseline 
characteristics of this adolescent cohort have been published with 55.2% of participants being 
TST positive (using a 5mm cut-off) and 50.9% being QFT positive at baseline[16]. Adolescents are 
currently under investigation as a target group for TB vaccines and the predictive value of IGRAs 
for the subsequent onset of TB disease will be helpful in planning clinical trials of novel TB 
vaccines. Such data are also necessary for policy makers, researchers, and clinicians developing 
guidelines for the use of such tests in TB Control Programmes and in clinical practice.  
 
Methods 
Ethics Statement: Written informed consent was obtained from the parents of participating 
adolescents and written informed assent obtained from each adolescent. This study was 
approved by the Faculty of Health Sciences Human Research Ethics Committee, University of 
Cape Town. Isoniazid prevention therapy (IPT) is not standard of care in South Africa for 
individuals with latent TB infection except for infants under the age of 5 and HIV positive 















Participants with a positive TST or QFT were investigated for TB disease and referred for 
treatment at public sector facilities if needed. 
 
Study setting: The study took place at an established TB vaccine trial site in the town of 
Worcester (and surrounding villages) approximately 100 km from Cape Town. This area has a 
high burden of TB with a total notified TB incidence rate among all ages of approximately 1,400 
per 100,000 population, based on official TB programme data for 2006 [17].  
 
Study subjects: Adolescents aged 12 to 18 years were recruited from high schools in the study 
area. They were not participating in a TB vaccine trial at the time of this study. 
 
Study procedures: Demographic data were collected at baseline, as well as data on current and 
prior household TB contact. At baseline, blood was drawn for QuantiFERON® TB Gold In-tube 
(Cellestis). A TST was then immediately administered using the Mantoux method on either 
forearm, using 2 tuberculin units of RT23 (Statens Serum Institut, Denmark).  Induration at the 
TST site was read 48 - 96 hours later with a ruler or a caliper by trained study personnel. Those 
with previous or current TB did not have a TST performed, because of the increased risk of 
severe allergic reactions. The QuantiFERON test (QFT) was performed as recommended by the 
manufacturers. Any participant who had TB related symptoms, a recent household contact, a 
positive TST >10 mm induration or a positive QFT were referred for two sputum smears. If either 
or both were sputum samples  were smear microscopy positive for acid fast bacilli, the sputums 















referred to the public health services for evaluation and treatment. About half of participants 
were allocated to active follow up three monthly and half to passive follow up being seen at 
baseline and at their two year visit only. At follow up visits, those with new symptoms, a new 
household contact, a converted TST (>10 mm increase from baseline) or a converted QFT test 
(change from negative to positive) were investigated for active TB. Investigation for TB included 
two sputum samples for smear microscopy on two separate occasions. If any single sputum was 
smear positive, a mycobacterial culture, chest x-ray, and HIV test were performed. In addition, 
surveillance was conducted at TB clinics and of hospital registers in the area to find any TB cases 
diagnosed in between visits in all participants.  All subjects were scheduled to be seen for a two-
year close-out visit unless they were lost to follow up or had died. Due to financial constraints, a 
small proportion of two-year visits were brought forward at th  end of the study. Follow up was 
therefore continued for a minimum of 22 months. Those completing “two-year” visits were still 
observed for the occurrence of cases through surveillance of health facility records until the last 
subject had their final visit, giving a maximum follow up time of 3.8 years. The study took place 
from 2005 to 2009.  
 
Analysis: Data were captured in a Microsoft Access database and analysed with STATA version 
11.0 (Statacorp, Texas, USA). A TST cut-off of 5 mm was used to define a positive or negative 
test based on the distribution of TST indurations[16]. Analyses based on the 10 mm and 15 mm 
cut-offs are also given. A QuantiFERON value of 0.35 international units or more was deemed 
positive as per manufacturer’s specifications. Any participant diagnosed with pulmonary TB 
based on at least two positive sputum smears or a single positive sputum culture was defined as 















total person time of observation. Observation time was calculated from date of enrolment to 
study end date except where there was loss to follow up, diagnosis of TB, consent withdrawal or 
death. When there was loss to follow up, person time of observation was calculated from 
baseline to a halfway point between the date when last seen and the date of the next scheduled 
visit when loss to follow up was established. 95% confidence intervals for incidence rates were 
calculated using Poisson regression. Incidence rate ratios (IRRs) were then calculated and the 
95% confidence interval for each IRR was calculated. Exposure to TB was based solely on 
reported household TB contact at baseline. Reported time between household TB contact and 
enrolment was calculated by subtracting the year of reported contact from the year of 
enrolment. The sample size for this study was based on estimation of an incidence rate that 
would be useful for planning clinical trials of new TB vaccines in adolescents. The sample size 
analysed would have been sufficient to detect a significant difference in predictive value 
between the TST positive and QFT positive groups at an incidence rate ratio of 1.54 given an 




6,363 participants were enrolled at baseline but after exclusion of those with prior or current 
TB, indeterminate QFT results, or missing QFT or TST results, as described elsewhere[16], 5,244 
participants were included in this analysis. 82% of participants completed follow up at two 
years. Of the 18% of participants who did not complete their two year visits, 8 (0.2%) had died 
during follow up. More detail on attendance at follow up visits and reasons for visits not being 















was 2.3 years, median 2.4 years and range 1.5 to 46 months (3.8 years). The most common 
reason for non-participation in this study when a reason was given was fear of blood draws. 
Important baseline characteristics of the recruited population were as follows: 54.2% female, 
56.9% under the age of 16, 93.8% reported having received BCG at birth and 25.4% reported a 
prior or current household contact. More details on baseline characteristics are laid out in Table 
1. 
 
Baseline TST and QFT results 
There was good agreement at baseline between QFT and TST at the 5 mm (84.8%, kappa 0.70) 
and 10 mm cut-off (81.4%, kappa 0.63) but not the 15 mm cut-off (64.3%, kappa 0.30) (details 
described elsewhere[16]).  
 
Incident cases and rates by TST/QFT status 
67 participants were diagnosed with TB, of whom 52 met the a priori case definition and 42 
were culture positive. Percentage agreement between TST and QFT among the 52 cases was 
86.5% (kappa 0.63). The incidence rates of TB by baseline QFT and TST status are shown in Table 
2 and Figure 1. These show that the TB incidence rate was 0.60 cases per 100 person years 
(pyrs) (95% confidence interval [CI] 0.43-0.82) for baseline TST positive (> 5 mm) participants 
and 0.64 cases per 100 pyrs (95% CI 0.45-0.87) for baseline QFT positive participants. There 
were 7 cases diagnosed within 6 months of enrolment and excluding these changed the rates to 
0.53 (95% CI 0.37-0.73) and 0.55 (95% CI 0.38 – 0.77) cases per 100 pyrs for positive TSTs and 















per 100 pyrs (95% CI 0.53-1.02) in participants with a baseline TST > 10 mm (42.2% of 
participants). There was a significantly higher rate of TB in those with a positive QFT or TST than 
in those with a corresponding negative test result. The incidence rate ratios (IRRs) were 2.7 (95% 
confidence interval [CI] 1.4-5.0) for TST (Incidence Rate (IR) TST+/ IR TST-) and 2.9 (95% CI 1.6-
5.2) for QFT (IR QFT+/ IR QFT-). The number of persons that needed to be tested for TST and/ or 
QFT and followed up to predict one TB case over a period of one year ranged from 157 to 520 
depending on the test result. The proportion of cases who were test positive and diagnosed 
with TB within the first year compared to subsequent years was 84.2% versus 72.7% (p=0.34) for 
TST and 73.7% versus 75.8% (p=0.86) for QFT respectively. 
 
Sensitivity, specificity, positive predictive value and negative predictive value (Table 3). 
Approximately three quarters of cases, 76.9% for TST and 75.0% for QFT (p=0.81), were test 
positive at baseline. Specificity was less than 50% for both tests: 45.0% for TST and 49.3% for 
QFT (p < 0.01). While this constituted a statistically significant difference, it was not viewed as 
clinically relevant. The positive predictive value was similarly very low for both (TST 1.4% and 
QFT 1.5%) and the negative predictive value was equally high for both tests (99.5%).  
 
Relationship between time of exposure and risk of disease 
In one subset of participants (n=1328) for whom a history of a household TB contact was 
reported at baseline, the prevalence of a positive baseline TST and QFT was significantly and 
negatively associated with time since TB contact exposure (Table 4); i.e. the longer the time 















cases for whom a TB contact prior to enrolment was reported, 15 (75.0%) had had a contact less 
than 5 years before enrolment and 5 (26.3%), 5 years or more. The proportion positive TST and 
QFT results among cases who reported recent compared to remote contacts were similar.  Rates 
of disease were higher amongst those more recently exposed than among those exposed >= 5 
years  previously. These differences were not significant since all incidence rate ratios had very 
wide confidence intervals which included one (Table 5). 
 
Discussion 
This is the largest study investigating the predictive value of TST versus an IGRA and it is one of 
few from a high burden setting (Table 6). A positive TST and QFT were both indicative of a higher 
risk of developing subsequent TB disease, and were equivalent in predicting incident TB disease. 
While the sensitivity was moderate, specificity and positive predictive values were relatively 
low, and negative predictive values were high. There was a trend for more recent reported 
exposure (<5 years) to be associated with a higher risk of disease than more remote exposure 
but the confidence intervals were very wide.   
 
This study is significant in that most of the other longitudinal studies examining this question 
were based largely on household contacts of TB cases[9,10,12,13,15,18,19,20] while those using 
a cohort methodology were much smaller by comparison[11,14]. The finding in this study of a 
similar predictive value for QFT and TST accords with that of studies in Turkey, the Gambia, 
Senegal, Norway and the Netherlands [10,11,12,13,15], but contradicts the findings of  the 
studies from Germany and Hong Kong[9,14]. It is thus still unclear whether IGRAs offer better 















perform differently in high burden compared to low burden countries and this may partly 
explain the differences seen amongst the different studies[21]. The study in The Netherlands 
was done amongst immigrants and the one in Norway amongst asylum seekers, populations 
that represent high incidence home countries rather than low incidence host countries[11,13]. 
In countries with a high burden of TB disease and therefore exposure to active TB cases, the 
greater specificity of IGRAs is apparently not useful. Also, where BCG is given at birth as is 
common in high burden countries, it has been shown that the effect of BCG on the TST is limited 
after the age of 10 and the TST thus retains its specificity[22]. These tests may therefore 
perform better in low incidence settings. Therefore, many low incidence countries have shifted 
to using IGRAs. The setting in which this study was done possibly has a low burden of NTMs. It 
may be that the IGRAs will perform better in settings where th re is higher exposure to NTMs 
due to IGRAs not being affected by most NTMs while the TST is. 
 
Table 6 summarises the studies comparing the predictive value of TST and IGRAs for TB disease 
and includes the data from this study. There are important differences amongst the studies – 
different products are compared, different cut-offs are used for TST and different populations 
have been studied. These design and measurement differences may also explain some of the 
different results obtained. This limits the degree to which these studies are comparable.    
 
The TB incidence rates in our cohort study are lower than in the contact investigation studies. 
Contacts are likely to have been more recently exposed whereas in a cohort study, time since 
exposure will vary. Recent contacts are at higher risk of progressing to disease within the first 















rate of disease of 36.9 per 1000 amongst household contacts compared to a 10 year rate of 6.6 
in a cohort of mental patients who were followed up[4]. In the household contact group in this 
American paper, most cases occurred in the first 5 years of follow up. The kind of cohort study 
reported in this manuscript helps to quantify risk in a clinical context where time since exposure 
is often not known.   
 
The lower proportion of TST and QFT positive results in those with a longer reported time 
between exposure and latent TB infection measurement by TST and QFT indicates waning of 
responses to TB antigens over time although this may also be affected by recall bias. When we 
examined risk of progression to disease in those who reported a prior household contact, there 
was a trend towards an increased risk in those with recent exposure but this was not significant. 
This study may have been inadequately powered to detect this difference. Also, one would need 
to recognize that in this community, the high burden of TB means that exposure is likely to be a 
common occurrence whether reported or not. A study amongst immigrants to the Netherlands 
showed that remote exposure is common particularly among those from high burden 
settings[23].  
 
There was no difference in proportion TST or QFT positive at baseline between cases diagnosed 
in the first year after enrolment versus those diagnosed afterwards. This may be due to the fact 
that follow up was not continued for long enough to detect a drop off in risk. The studies 
reviewed by Ferebee show a sustained high risk in those with a recent contact in the first five 
















Despite the higher risk of subsequent TB represented by a positive TST or QFT, the number of 
people that must be followed up and screened for TB in order to find a single case is substantial, 
even in this high burden setting where infections and re-infections are  common[24]. The cost 
effectiveness of such population screening would need to be evaluated, including the value of 
treating test positive persons with isoniazid preventive therapy to prevent the onset of future 
TB disease.  Given that across most studies, more than 95% of persons who are IGRA positive do 
not progress to TB disease, emphasises the need for biomarkers other than interferon gamma 
for risk prediction, or a combination of interferon gamma with risk factors (e.g. age, contact 
history, conversion) to enhance predictive value. 
 
Positive and negative predictive values are dependent on prevalence. Since a low positive 
predictive value was achieved in a high burden setting, an even lower PPV can be expected in a 
low burden setting.  The findings on sensitivity, specificity, positive and negative predictive value 
are similar to those in The Netherlands study[13] while the other studies did not describe these.  
While a positive test is not very helpful in predicting disease, a negative test suggests that risk of 
progression to disease is low although it does not rule out the possibility entirely.  
 
These results are not representative of adolescents with prior TB since they were excluded from 
having a TST. Since those with past TB are at higher risk of getting TB again [25], our incidence 
rates were possibly all underestimated. Incidence rates of those with prior TB could not be 















However, incidence rates could be calculated for those with a history of prior TB with a positive  
baseline QFT and the rate for them was 0.66/ 100 pyrs (95% confidence interval 0.27-1.37). This 
is similar to those with a positive baseline TST or QFT without a history of prior TB. One can then 
reasonably assume that the rate would have been similar in those who had prior TB who would 
have had a positive baseline TST. A positive QFT (and presumably TST) did not therefore predict 
a higher risk of TB in those with prior diagnosis of TB in this study. Since those with past TB are 
also more likely to be TST and QFT positive, it is unclear how sensitivity, specificity, PPV and NPV 
would change, had we included those.  Also, any of those negative at baseline could have 
converted during study follow up due to new exposures prior to the onset of TB disease and 
would be misclassified as test negative. There is no reason to think that this would have 
occurred differentially between the tests. Those with a positive TST or QFT at baseline were 
investigated for TB. If diagnosed with TB, they were not included in the 5244 participants 
analysed in this predictive analysis. Those with a QFT or TST conversion were investigated at 
follow up and if diagnosed were included in the analysis. However, most cases (>80%) were 
diagnosed by local health services who would not normally have enquired about TST and QFT 
results since these are not routinely used in the diagnosis of TB in this age group. Therefore 
neither incorporation bias nor lack of blinding were felt to be major factors influencing the 
analysis. While the screening methods for TB at baseline were insensitive for smear negative 
culture positive TB, a sensitivity analysis which excluded cases diagnosed within six months of 
enrolment did not appreciably change the main findings showing no difference in the predictive 
value of TST versus QFT for TB disease. Not all participants completed follow up; if any of these 
had developed TB, this may have influenced the findings in that rates would have been higher. 















participate, these results are not representative of all adolescents in this area. None of these 
limitations are thought to affect the comparison between TST and QFT in this study. 
 
These findings suggest TST and QFT are equally predictive of progression to TB disease in a 
cohort of adolescents in a high TB burden population and may be used interchangeably. Our 
results do not support the hypothesis that QFT is superior to TST in its predictive value. These 
findings should assist policy makers attempting to develop guidelines for IGRA use in high and 
low TB burden countries. More studies in high burden settings and in adolescents are needed to 
indicate whether either the TST or QFT may be used as a screening tool in planning TB vaccine 
trials in adolescents. 
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Figure 1: Incidence rates by baseline TST and QFT status. 
 
Figure 1 is a chart of incidence rates of tuberculosis per 100 person years of observation by 
baseline TST and QFT status. Firstly, rates are shown individually for either positive or negative 
TST or QFT result. Then rates are shown with combined results, either concordant negative or 















Table 1: Demographic profile of study participants analysed (n=5244) 
Category Numbers (column %) 
Gender 
Male  2,402 (45.8%) 
Female 2,842 (54.2%) 
Age (years) 
>15  2,261 (43.1%) 
<15 2,983 (56.9%) 
Racial group  
Black  995 (19.0%) 
Mixed race 3,839 (73.2%) 
Indian/ white 410 (7.8%) 
Parent income:  classified on at least one parent’s income 
<R4000 /month  4,243 (80.9%) 
>R4000 /month  921 (17.6%) 
Unknown 80 (1.5%) 















< Primary school  1,510 (28.8%) 
>  High school  2,890 (55.1%) 
Unknown: 844 (16.1%) 
Paternal highest education level 
< Primary school  686 (13.1%) 
> High school  1,720 (32.8%) 
Unknown: 2,838 (54.1%) 
BCG reported as being given 
No  46 (0.9%) 
Yes 4,917 (93.8%) 
Unknown  281 (5.4%) 
BCG scar 
Absent  1,490 (28.4%) 
Present 2,064 (39.4%) 
Unknown (Not sure) 1,690 (32.2%) 
Current or prior TB household contact  















No  3,911 (74.6%) 
Unknown 1 (0.02%) 
Chronic allergy-related conditions e.g. asthma, hay fever, 
eczema 
Yes  53 (1.0%) 
No 5,191 (99.0%) 
History of hospitalization within the 6 months prior to 
enrolment 
Yes 46 (0.9%) 















Table 2: Incidence rates by TST (>5mm) and QFT status at baseline. 
 






(per 100 person 
years, 95%CI) 
No of persons 
followed up per 
year to detect 1 
case 
TST+ 2,894 40 6651 0.60 (0.43-0.82) 166 
QFT+ 2,669 39 6137 0.64 (0.45-0.87) 157 
TST- 2,350 12 5337 0.22 (0.11-0.39) 444 
QFT- 2,575 13 5851 0.22 (0.12-0.38) 450 
TST+/QFT+ 2,383 36 5480 0.66 (0.46-0.91) 152 
TST-/QFT+ 286 3 657 0.46 (0.09-1.33) 219 
TST+/QFT- 511 4 1171 0.34 (0.09-0.87) 293 
TST-/QFT- 2,064 9 4680 0.19 (0.09-0.37) 520 
Total* 5,244 52 11988 0.43 (0.32-0.57) 231 
















Table 3: Sensitivity, specificity, positive predictive value and negative predictive 
value of TST and QFT for predicting TB disease. 
 
 TST  % (95% CI) QFT  %(95% CI) 
Sensitivity 76.9 (63.6 – 87.5) 75.0 (61.1 – 86.0) 
Specificity 45.0 (43.7 – 46.4) 49.3 (48.0 – 50.7) 
Positive Predictive value 1.4 (1.0 – 1.9) 1.5 (1.0 – 2.0) 
















Table 4: Proportion TST and QFT positive by time since recalled exposure to 
household TB contact (N=1,328) 
 QFT positive (%) TST positive (%) 
0-4 years (n=890) 69.4 72.3 
5-9 years (n=235) 65.1 72.8 
10-14 years (n=168) 57.1 67.3 
>15 years (n=35) 57.1 54.3 

















































890 15 0.74 15 1.07 14 0.95 
Remote >5 
years 
438 5 0.49 3 0.48 4 0.56 
Incidence rate ratio  1.5   2.2   1.7  
(Recent/ remote) (95% 
confidence intervals) 
 (0.5-5.3)  (0.6– 11.9)  (0.5-7.0) 
 
*As reference, those with no exposure had an overall incidence rate of 0.36/ 100 pyrs (95% CI 
0.25-0.51), those with a positive TST 0.49/100 pyrs (95% CI 0.31-0.75) and positive QFT 0.51 















Table 6: A summary of longitudinal studies comparing the predictive value of TSTs and IGRAs. 
Authors, Country and Year of 
publication  
Study Type  Number  Population 
description 
Cases  Length of 
Follow up  
Products and TST cut-offs  Baseline 
prevalence  
Cumulative incidence (%) or 
Incidence rate per 100 person years 
(pyrs)* 
R Diel et al. Germany (2010) Contact 
investigation 
903 All ages - range 1-62 19 Up to 4 yrs  TST > 5 mm 63% 3.2%  
      TST > 10 mm 25% 4.8% 
      QFT 21%   12.9% 
P Hill et al. Gambia (2008)  Contact 
investigation 
2348 All ages 26 2 yrs  TST > 10 mm 36% 0.9/ 100 pyrs 
      Elispot 28% 0.9/ 100 pyrs 
S Kik et al. The Netherlands (2009) Contact 
investigation 
339 Immigrants > 16 
years 
9 2 yrs  TST > 10 mm  54%   3.1%   
      QFT  55% 2.8%   
      T-Spot 63% 3.3%   
M Bakir et al. Turkey (2008) Contact 
investigation 
908 Age < 16 years 15 2 yrs  TST > 5 mm 61% 1.7/ 100 pyrs 















CC Leung et al. Hong Kong (2010) Cohort study 308 Adult males with 
silicosis 
17 1-5 yrs TST > 5 mm 74% 2.3/ 100 pyrs 
      TST > 10 mm 66% 2.6/ 100 pyrs 
      T - Spot 66% 3.2/ 100 pyrs 
C Lienhardt et al. Senegal (2010) Contact 
investigation 
2679 All ages 52 2 yrs TST > 5 mm 78%  1.5/ 100 pyrs 
      TST > 10 mm 65% 1.2/ 100 pyrs 
      TST > 15 mm 37% 1.6/ 100 pyrs 
      Elispot 65% 1.4/ 100 pyrs 
H del Corral et al. Colombia (2009) Contact 
investigation 
2052 All ages 37 2-3 yrs Elisa (IFN-γ responses to 
CFP-10) 
66.3% 0.8/100 pyrs 
H Mahomed et al. South Africa Cohort study 5244 Adolescents aged 
12-18 
52 2-4 yrs  TST > 5 mm 55% 0.6/ 100 pyrs 
      TST > 10 mm  42% 0.7/ 100 pyrs 
      QFT 51% 0.6/ 100 pyrs 
 














Table S1: Flow of visits and reasons for visits not taking place. (Supplementary table) 
This table describes frequency of visits, the number of visits at each time point and the reasons 
for visits not being completed. It also provides the number for each reason with percentages. 
Visit  Died  Other Loss to Withdrew Missed Seen Not Seena Total 
Day   follow up   Visits 
 90 1 0 18 12  5 2,765 2,443  5,244  
% 0.02 0.00 0.34 0.23  0.10 52.73 46.59  100.00  
180 1 0 62 73  29 2,636 2,443  5,244  
% 0.02 0.00 1.18 1.39  0.55 50.27 46.59   100.00  
270 1  0 69 77  19 2,635 2,443  5,244  
% 0.02 0.00  1.32 1.47  0.36 50.25 46.59   100.00  
360 1 1 87 159  33 2,520 2,443   5,244  
 % 0.02  0.00 1.66 3.03  0.63 48.05 46.59   100.00  
450  2 1 90 162   23  2,523 2,443   5,244  
% 0.04 0.02  1.72 3.09   0.44 48.11      46.59   100.00  
 540  2 1  133  261   52 2,352  2,443  5,244  
  % 0.04  0.02 2.54  4.98  0.99  44.85  46.59   100.00  














% 0.04 0.02 2.78 5.38  2.86 42.33 46.59  100.00  
720  8 0 409         537  0 4,290 0   5,244  
 % 0.15 0.00  7.80 10.24  0.00 81.81 0.00  100.00 
 
a Roughly half of participants were followed up three monthly and half were seen at baseline 
and two year visit. These figures reflect the group only seen at baseline and day 720 visits. This 
component of this study will be dealt with in a separate manuscript and does not have any 















Chapter 7: Are adolescents ready for tuberculosis vaccine trials? 
 
Paper overview 
This analysis reports on a quantitative and qualitative assessment of adolescents and their 
parents’ attitudes towards participating in tuberculosis (TB) vaccine trials. 
Contribution to the thesis and novelty 
This paper addresses the fifth objective of the thesis. TB vaccine trials in adolescents are 
planned for the future. While studies in the HIV and human papilloma virus vaccine fields have 
been done to assess knowledge and attitudes towards vaccine trials, no studies had been done 
in any populations examining knowledge of TB and attitudes towards TB vaccine trials. This 
study was thus unique and provided useful insights that would be helpful in planning TB vaccine 
trials in adolescents.   
Contributions of candidate 
I was the first author on the publication and was primarily responsible for overseeing the 
conduct of the study on which the publication is based. I was also primarily responsible for the 
data analysis and write-up of the study and this is clear from the roles of co-authors as described 
below.  
Role of authors: 
H Mahomed: Conceived the study, wrote the protocol, responsible for study design, 
oversaw the conduct of the study, analysed the data and wrote the manuscript. 
J Shea: Was responsible for qualitative component of the study design, conducted the 















F Kafaar: Was the study co-ordinator responsible for day to day management of the 
study and reviewed the manuscript 
T Hawkridge: Reviewed and commented on the protocol and reviewed the manuscript 
WA Hanekom: Reviewed the manuscript 
GD Hussey: Reviewed and commented on the protocol and reviewed the manuscript 
 
Publication status 
Submitted: 13 June 2007 
Accepted: 13 June 2008 
Published: (on line) 11 July 2008 as: 
Are adolescents ready for tuberculosis vaccine trials? Mahomed H, Shea J, Kafaar, F, Hawkridge 
T, Hanekom WA, Hussey GD. Vaccine 2008; 26:4725-4730. 















Are adolescents ready for tuberculosis vaccine trials? 
  
H Mahomed a,b, J Shea b, F Kafaar a,b, T Hawkridgec , WA Hanekom a,b, GD Hussey a,b 
a South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular 
Medicine, b School of Child and Adolescent Health, University of Cape Town, South Africa, c Aeras 
Global Tuberculosis Vaccine Foundation 
 
 
Address for correspondence: H Mahomed  
South African Tuberculosis Vaccine Initiative (SATVI), 
Institute of Infectious Disease and Molecular Medicine, 
University of Cape Town Health Sciences Faculty, 
Anzio Rd, Observatory, Cape Town 
South Africa 
7925 
















Tuberculosis vaccine trials are planned in adolescents in a high tuberculosis burden rural area 
near Cape Town, South Africa. To determine the knowledge and attitudes of adolescents about 
tuberculosis, vaccines and vaccine trials, a representative sample of adolescent learners was 
chosen from high schools in the trial area. A questionnaire was administered and focus group 
discussions held with the group and a sample of their parents. The questionnaire response rate 
was 65%.  Knowledge of tuberculosis was fair (63.7%) but knowledge of vaccines poor (41.9%) 
based on a TB and vaccine knowledge score respectively. Willingness to participate in vaccine 
trials will be influenced by the type of procedures involved (60% willing to answer questions, 
43% willing to be examined, 32% willing to undergo skin tests and 39% willing to undergo blood 
draw). In general, better knowledge was statistically associated with greater willingness to 
participate in study procedures except for the blood draw. The focus group discussions showed 
that adolescents and their parents were positive about participating in vaccine trials but 
concerns about safety and the provision of adequate information should be considered when 
planning TB vaccine trials. This study suggests that TB vaccine trials would be acceptable 
amongst adolescents in this community with certain provisos. 
 
 
Key words. : Tuberculosis, Vaccine, Survey, Adolescents, Parents.  
 

















Tuberculosis (TB) is a major part of the disease burden in South Africa and worldwide with one 
third of the world’s population estimated to be infected with Mycobacterium tuberculosis [1]. 
The existing vaccine against tuberculosis, bacillus Calmette Guérin (BCG) has had a limited 
impact on the tuberculosis epidemic and new tuberculosis vaccines are being developed. [2,3]. 
The South African Tuberculosis Vaccine Initiative (SATVI) and the Aeras Global Tuberculosis 
Vaccine Foundation are planning clinical trials of new TB vaccines in adolescents in a rural area 
just outside of Cape Town hereafter referred to as “the study area”.  In the study area, the 
reported new smear positive rate of pulmonary TB is high (564/100 000 in 2004) [4].  
Adolescents are considered a target group for TB vaccines due to the fact that the rate of TB in 
high burden countries starts to increase in adolescence (5).  
 
The success of a TB vaccine trial in adolescents would be reliant on adolescent willingness to 
participate and the consent of their parents. The authors did not come across any studies 
reporting specifically on the feasibility and acceptability of conducting TB vaccine trials in 
adolescents.  It was thus considered to be important to investigate the knowledge and attitudes 
to TB, vaccines and research amongst adolescents and their parents. 
 
While some studies have investigated knowledge levels with regard to HIV in adolescents [6], 














To our knowledge, no study involving procedures such as drawing of blood and skin tests has 
been conducted before in the study area’s adolescent population.  
 
This study was designed to determine knowledge levels about TB and vaccines amongst 
adolescents, their attitudes and that of their parents towards research and invasive procedures 
(including HIV testing), the factors which influenced their attitudes and what factors an 
advocacy or recruitment campaign should take into account when trying to promote adolescent 
participation in clinical research. Potential barriers to the success of the TB vaccine trials were 
explored in focus group discussions with adolescents and their parents. The adolescents studied 
in this research were learners attending high schools in the study area.  Because TB rates are 
higher in poorer communities, differences in responses between high and low socio-economic 
groups were explored. Prior to this study, the Director of the local Department of Education, 
school managers (known as circuit managers), school heads (principals) and teachers were 
engaged through meetings with respect to conducting TB vaccine trial research amongst school 
learners. All these stakeholders responded positively to the planned research activities and it 
was felt not necessary to specifically survey their views as part of this study. 
 
In South Africa, anonymous HIV testing is conducted annually amongst pregnant women to 
determine epidemiological trends. The women tested are not informed of their results. In 
preparation for TB vaccine trials in adolescents, HIV trends amongst adolescents would be 
important to know because of the increased risk of TB amongst those who are HIV positive.  The 
authors wished to explore how adolescents would feel about such epidemiological prevalence 














part of the screening process for entry into new TB vaccine clinical trials and adolescents not 
wishing to know their HIV status may be reluctant to participate in such trials as a result.  
2. Materials and Methods 
 
Study population: High school learners in all grades at the 11 schools in the study area and their 
parents. 
Study design: A cross-sectional study involving questionnaires and focus group discussions. 
Sample: For the questionnaires, one class from each of the eleven schools was selected with an 
even distribution by grade as follows: 2 classes from grades 8, 9, 11 and 12, and 3 classes from 
grade 10. 
 
Grades were randomly chosen by drawing the name of a school from one box and then the 
name of a grade from another box. 
 
For the focus group discussions, one class per grades 8-11 was chosen from amongst the above 
classes (the highest grade, grade 12 was excluded from the focus group discussions to minimise 
disruption of their final year of school).  Ten learners were then randomly selected from the 
class lists. The parents of these learners were interviewed separately for the parent focus group 
discussions. 
The focus groups were asked to attend specially arranged sessions of one and a half to two 














Study tools: A self administered, multiple choice, paper questionnaire made up of 19 closed 
questions explored knowledge levels of infectious diseases and vaccines, and attitudes to 
research amongst learners. The questionnaires were administered in the two languages used in 
the study area, Afrikaans and Xhosa and took learners about half an hour to complete them. The 
content of the questionnaires was pre-tested amongst a group of adolescents from Cape Town 
and this resulted in a few minor changes to the questionnaire. The first focus group discussion 
with learners was used to check the suitability of the questions in the questionnaire and this 
also resulted in a few minor changes. Thereafter, the questionnaire survey and focus groups 
were conducted over the same period. Those answering the questionnaire were told that more 
than one answer could be marked per question. No demographic information such as age and 
gender or any other additional information was collected as part of the survey in order to 
reduce the risk of deductive disclosure of the survey participants and to encourage honest 
responses. (Sometimes, young adults still attend high school in South Africa. However, all 
participants required parental consent for participation and therefore must have been under 
the age of 21.) 
 Focus groups discussions were held separately with learners and parents to determine attitudes 
towards medical research, invasive procedures and infectious diseases using a set of guide 
questions. Guide questions were thus used to solicit responses initially but further discussions 
were based on the responses given to these questions. When an Afrikaans speaking group was 
interviewed, the facilitator conducted the discussion in Afrikaans. When a Xhosa speaking group 
was interviewed, the assistance of a translator was obtained. 
Ethical issues:  Permission was obtained from the Department of Education to do the study.  














was conducted in the language of preference of the participants.  The study was approved by 
the Research Ethics Committee of the Faculty of Health Sciences of the University of Cape Town. 
Data capture and analysis: The questionnaires were captured in Microsoft Excel and analysed 
with EPI info 3.3.2. When “unsure” was indicated as an answer, these were counted as incorrect 
for the purpose of knowledge measurement. The schools were divided into two groups 
according to financial subsidies received from the Department of Education based on socio-
economic status. Group A, the schools from a higher socio-economic status comprised one 
grade 8, two grade 9, one grade 10 and one grade 11 class and group B, the lower socio-
economic status schools comprised one grade 8, two grade 10, one grade 11 and two grade 12 
classes.  Responses to the questionnaire were then compared between the 2 groups. The 
responses to knowledge questions were compared with willingness to undergo procedures 
using summary measures of the TB and vaccine answers. Binary variables were created for 
vaccine knowledge and TB knowledge. Three correct answers were considered knowledgeable 
for TB knowledge, and two for vaccine knowledge. Proportions were compared using relative 
risks and 95% confidence intervals. Knowledge of TB was compared to knowledge of vaccines 
using a kappa statistic.  
 
The focus group discussions were recorded using an electronic dictaphone. A recorder manually 
kept notes of the discussion. The tape recordings were transcribed and translated verbatim. 
Field notes were translated and transcribed and all transcripts were reviewed for completeness 
by two independent reviewers. The transcripts were used for content analysis to identify the 
main themes and were then coded for retrieval and analysis. Where appropriate, quotations 
















270 (65%) of 414 learners targeted completed the questionnaire. The response rate ranged from 
31-98% amongst the schools. It was 75% in more affluent schools (group A) and 59% in the less 
well-off schools (group B) (Relative Risk 1.28; 95% confidence interval 1.12 – 1.47). 
 
The learner focus groups were well attended with 10 participants attending sessions at each of 
the 4 schools selected.  The parent groups were less well attended with attendance ranging 
from 4-8 per focus group. 
Questionnaire results 
Knowledge results for all learners are set out in the first column of Table 1. Approximately three 
quarters correctly answered 3 of the 5 TB knowledge questions. Only half knew that the direct 
cause of TB was a germ while half incorrectly felt that smoking was the direct cause.  
 
Only 41% knew that vaccines were given to prevent infections, 25% knew that vaccines were 
made of “bits of dangerous germs that have been made safe” and 41% knew that smallpox no 
longer occurred due to a worldwide vaccination programme. The percentages reporting 
“unsure” as an answer for these 3 questions were 29%, 33% and 31% respectively.  74% knew 
that research is “when scientists want to find out something new”. The learners from the better 
resourced schools serving a higher socio-economic group (Group A) tended to have correct 
answers more often than the less resourced schools’ learners (Group B) particularly with respect 















In summarising the knowledge data, 63.7% (Group A: 67.5% and Group B: 60.4%, Relative Risk 
1.12; 95% confidence interval 0.93 – 1.34) of participants were knowledgeable about TB (as 
defined above) and only 41.9% (Group A 55.6%: and Group B: 29.9%, Relative Risk 1.86; 95% 
confidence interval 1.39 – 2.50) for vaccines.  Percentage agreement between those 
knowledgeable about TB and those knowledgeable about vaccines was 61.9% (kappa = 0.27).   
 
Fifty percent said they would like to know if they have HIV, 24% felt that they were not at risk of 
HIV and only 3% admitted to having already had an HIV test. 
 
Participants indicated that their willingness to participate (Figure 1) would be positively 
influenced by the provision of more information (66%), the research benefiting the community 
(33%), benefiting the school (33%), personal benefiting the participants  (31%) or if someone 
known to the participants monitored the research (21%). 
 
In response to the following question “Who would assist you in deciding on whether to 
participate in a research project?”, parents were by far the most commonly cited (70%), 
followed by friends (27%), teachers (24%), siblings (13%) and other (11%).  As far as source of 
health information was concerned, parents (54%), teachers (47%) and health facilities (41%) 















When comparing attitudes to research procedures by socio-economic group, little difference 
was observed (table 2) with the greater willingness of learners from more affluent schools to 
answer questions being the only variable with a statistically significant difference.  However, 
learners from less well resourced settings tended to be more interested in knowing their HIV 
status than those from the better off schools. Benefiting personally from the research was more 
important to learners from the better resourced schools. 
 
Summary knowledge of TB, summary knowledge of vaccines and a correct response to the 
question on research was compared with willingness to participate in different procedures 
(Table 3).  In general, greater knowledge was likely to be associated with greater willingness to 
participate in procedures. However, knowledge of TB and vaccines was not statistically 
significantly associated with willingness to undergo a blood draw. 
 
Analysis by grade was conducted but no clear trends emerged with socio-economic group 
tending to have a greater influence on responses than grade. 
 
Focus group discussion (FGD) results for the parent group 
Reasons for Participating: 
 
The general feeling amongst parents was that the research would have educational, societal and 














as reflected in the verbatim quotes provided as follows: “How do we know that you are not 
going to inject our children with TB so that you can study them?”, “But is the vaccine safe to use 
in people?” and “What if we get side-effects?” 
 
Research Exposure: 
Parents reported minimal prior exposure to research apart from market surveys conducted in 
shopping centres.  
 
Perceptions about TB research and TB itself 
Generally, parent participants felt very strongly that TB vaccine research is needed and that a 
new vaccine would be of enormous benefit to their communities. Those from a more affluent 
community had fewer family members with TB than those with a lower socio-economic status.  
 
TB Stigma: 
Participants had faith in TB treatment and felt that as long as people remained faithful to taking 
their medication, they had no reason to ostracise anyone who had TB. 
 














Parents had no particular preference in terms of the TB screening location. They agreed that a 
clean and safe environment is a significant prerequisite for conducting the research. A 
designated area at a school or the local health facility was acceptable. 
 
Study/Screening Staff: 
Parents, like their adolescent children identified professional competence, neatness and 
cleanliness, confidentiality, trustworthiness and friendliness as very important characteristics for 
research staff. Gender and age were not considered important. They expressed a hope that the 




Parents were particularly concerned about the safety and side-effects of the proposed new 
vaccine. They referred to the scarring on the right upper arm, the site of BCG vaccination, and 
they wanted reassurance that the new vaccine had been approved as being safe for use in 
human subjects. 
 
Focus group results for the adolescent group 















The reasons given for their participation in the research included curiosity, an interest in 
understanding more about TB and most importantly a desire to make a contribution to a body 
of knowledge that can be of benefit to the larger, and often less privileged, population.  
 
Research Exposure: 
As with their parents, the exposure of adolescents in this community to research was limited to 
market type surveys or no exposure at all.  
 
Perceptions about TB research and TB itself 
Most participants regarded the TB research as being very important and acceptable. Given the 
high prevalence of TB in the region, it was not surprising that there was a heightened awareness 
of the need for TB –related research.  Those adolescents attending the predominantly Xhosa-
speaking school expressed a fear of TB and associated it with death. Participants also wanted 




The degree of stigmatization varied from: “If I am exposed to a person with TB then my immune 
system must take care of it, I can’t go about avoiding people” to “Yes I would feel a bit 
uncomfortable [being with a person with TB]” and finally an admission that “It would be better if 















TB Screening Site: 
Absolute assurance of privacy and confidentiality was considered essential if a dedicated space 
on the school premises were to be used for the study.  
 
Adolescent participants drawn from the predominantly “Xhosa” school were more likely to 
associate TB with shame and stigma. Consequently their preference for TB screening was a 
venue away from the school.  
One respondent said: “If you come to school and then everybody will see me going to that TB 
room and then they will talk and I will feel bad.” 
 
Study/Screening Staff: 
The highly valued characteristics for research staff were as mentioned above for the parent 
group. Gender and age were not considered to be significant characteristics. 
 
HIV testing 
Most were opposed to the idea of anonymous HIV testing and if tested would want to know the 
















Immunization was not known to be a TB prevention strategy and a large proportion of 
participants did not know whether they had been immunized. A common concern expressed in 
every focus group session related to the safety and side-effects of a new TB vaccine.  This 
concern was expressed by a 15 year-old boy: “I heard that vaccines can be dangerous because 
they have traces of mercury. Is that true?”  
 
Once an explanation of the procedures of testing a vaccine in the laboratory and the standards 
to which vaccines have to conform prior to testing on human subjects was given, the majority of 
these parents and their children found TB vaccination to be highly acceptable, suggesting that 




These results showed a fair knowledge of TB amongst the high school adolescents in this 
community but a poor level of knowledge about vaccines.  Willingness to participate in research 
varied depending on the type of procedures involved.  While there were differences in 
knowledge levels between lower and higher socio-economic groups, attitudes to research were 
similar. However, there was a distinct difference in attitudes towards HIV testing with children 
from poorer families being more interested in knowing their HIV status than children from more 
well off families. The provision of information on the research and the involvement of parents 














Willingness to participate in research procedures was in general associated with knowledge of 
TB and vaccines. However, this was different with phlebotomy as knowledge of TB and vaccines 
were not significantly associated with willingness to undergo a blood draw. 
 
The fair levels of knowledge about TB may reflect the high degree of prior contact with 
community or family members with TB which these adolescents have experienced as indicated 
by the focus group discussions. The poor level of knowledge about vaccines is of concern.  The 
normal school curriculum does not include any health education on vaccines. This policy should 
be reviewed since vaccines for human papilloma virus (HPV), HIV and TB as well as boosters for 
other vaccines are being considered in adolescence. Lack of knowledge may inhibit participation 
in clinical trials and underscores the need by organisations considering vaccine trials to have an 
education campaign regarding vaccines amongst adolescents. This is supported by the finding 
that knowledge of vaccines and research was significantly associated with willingness to 
participate in research procedures in most instances. A review of HIV/AIDS knowledge amongst 
South African youth showed that while youth knew about AIDS, they were less familiar with HIV 
[7]. Specifically, youth were less familiar with how HIV is transmitted and about the 
asymptomatic HIV carrier status. The implication of this for this study is that while the 
adolescents surveyed in this study showed a fair level of knowledge about TB, there may be a 
lack of depth in their understanding. In a study on HPV in Finland, 79% of parents and only 33% 
of adolescents had heard of HPV but 86% of adolescents were willing to accept vaccination 
against HPV should it become available [8]. The authors of this study also recommended 
improving knowledge and awareness of HPV as a way of dealing with potential resistance to 














they had heard of HPV [9]. Of course, knowledge itself would not be sufficient to change 
attitudes. The national risk survey in South Africa [6] indicated high levels of exposure to HIV 
education but adolescents still participated at high rates in high risk sexual practices.  This 
suggests that any education strategy with respect to vaccines should be carefully thought 
through if the intention is to change attitudes and behaviour. 
 
The differences in levels of knowledge between high and low socioeconomic groups are 
probably a reflection of differences in resources between the schools as well as differences in 
home circumstances.  The usefulness of this information is that it could help educational 
campaigns in their design and targeting.  Poorer communities would have the higher rates of TB 
and would benefit most from a TB vaccine.  For these reasons, their participation in TB vaccine 
trial would be crucial but informed consent principles would require that their participation 
must be based on a sound understanding of what such participation would mean. 
 
Anonymous HIV testing in this group was not perceived positively and this should be taken into 
account when anonymous HIV testing is considered in other studies. Anonymous HIV testing is 
utilised as a means of determining HIV trends in epidemiological studies. However, since ARVs 
and TB preventive therapy are benefits that are available to someone who knows his or her HIV 
status, it would not be easy to justify the anonymous testing. 
 
Differences seen in willingness to test for HIV between the socioeconomic groups probably 














about what type of person is at risk or current sexual practices. Certainly, the proportion of 
school learners participating in high risk behaviour as indicated by a national survey [6] 
emphasises the importance of HIV testing in this group. The one HPV study quoted above from 
the USA found that women from lower income families were more willing to accept HPV 
vaccination for girls than higher income families [9].  
 
The differences in willingness to participate in different procedures are understandable given 
that some procedures such as phlebotomy and tuberculin skin testing involve some degree of 
pain or discomfort.  This is likely to be a key determinant in recruitment for TB vaccine trials as 
both of these latter procedures are likely to be part of study screening procedures.  A South 
African study amongst adolescents looking at willingness to participate in HIV vaccine trials 
found that increasing age and length of residence were significantly associated with willingness 
to participate [10]. Provision of study information is likely to play a key role in getting adolescent 
agreement to participate and also that parents will play a key role in influencing adolescent 
participation. This allows for clear strategies to be formulated for achieving high levels of 
adolescent participation in TB vaccine trials. Roughly, one third of participants (31%) would want 
some personal benefit from participating. This option was the least highly rated but still 
represents a substantial proportion. A study looking at the recruitment and retention of Latino 
adolescents in clinical trials in the USA mentions incentives as being important to enrolling and 
maintaining adolescent participation. [11]. Parental and peer support also came out as 















C Mathews et al found in a study in South Africa on parental consent for school-based HIV/AIDS 
prevention research that while a large majority of parents provided postal consent for their 
children to participate, subsequent follow up showed that a lower proportion seemed to have 
actively participated in the consent process [12]. There would thus need to be clear processes to 
ensure both parental and adolescent informed consent in any planned TB vaccine trial. Trial 
organisers will have to prepare carefully regarding how procedures are explained during the 
consent process and then conducted in practice so as to minimise impact on recruitment.  
 
The response rate of 65% and the variation amongst the schools probably indicates that those 
less interested in research are under-represented in the results and that this would need to be 
considered in interpreting the findings. The statistically significantly higher response rate for 
affluent schools means that their views are over represented in these findings. Because one 
class per school was selected, and because better resourced schools tend to have fewer classes 
per grade, this is another reasons why the views of better resourced schools are probably over 
represented in this study. Literacy levels may have affected the results particularly with respect 
to the comparison between the socioeconomic groups although every attempt was made to 
phrase the questions as simply as possible. Since the questions in this study were not 
particularly sensitive except for the one on HIV testing, it is felt that the answers given were 
reasonably reliable. The review on HIV/AIDS knowledge amongst South African youth referred 
to above [23] indicated that surveys using open ended questions showed lower levels of 
knowledge than those using closed questions.  Because the questionnaire part of this study used 
closed questions in a multiple choice format, knowledge amongst adolescents might have been 














have added useful information on the age and gender distribution of the parameters assessed 




TB vaccine trials amongst adolescents in this community are clearly acceptable provided that a 
number of preparatory steps are undertaken.  Knowledge about vaccines in general and about 
TB vaccines specifically needs to be improved.  A clear explanation of the types of procedures 
involved in TB vaccine trials and the risks involved should be outlined. Mechanisms should be 
put in place to minimise the negative aspects of invasive procedures that are undertaken in 
clinical TB vaccine trials. Parents should be fully involved at an early stage in the research 
process as their attitudes would have a strong influence on adolescent participation. Different 
strategies may be needed for different socio-economic groups. 
Acknowledgements 
 
The authors would like to thank the Department of Education, the staff of the schools who 
agreed to participate and the learners and parents who participated directly in the study, 
Shiraaz Ismail for assisting with recording and transcription of focus group sessions, Alan Flisher 
and Catherine Mathews of the University of Cape Town for advice given in the design phase of 
the study, Suzanne Verver and Ellen Mitchell of the KNCV TB Foundation in the Netherlands who 
















1. Global tuberculosis control: surveillance, planning, financing. WHO report 2006. Geneva, 
World Health Organisation (WHO/HTM/TB/2006.362). 
2. Wiker HG, Mustafa T, Malen H, Riise AMD. Vaccine approaches to prevent tuberculosis. 
Scand J Imm 2006;64:243-50. 
3. Skeiky YAW, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 
2006;4:469-476.  
4. Groenewald P, Dept of Information Management, Boland-Overberg Regional Office Annual 
Health Status Report 2004, Worcester, South Africa: Department of Health, Boland-
Overberg Region, 2005. 
5. Weber HC, Beyers N, Gie RP, Schaaf HS, Fish T, Donald PR. The clinical and radiological 
features of tuberculosis in adolescents. Ann Trop Paediatr 2000;20:5-10. 
6. Reddy SP, Panday S, Swart D, Jinabhai CC, Amosun SL, James S, Monyeki KD, Stevens G, 
Morejele N, Kmabaran NS, Omardien RG and Van Den Borne HW. Umthenthe Uhlaba 
Usamila - The South African Youth Risk Behaviour Survey 2002. Cape Town: South African 
Medical Research Council, 2003. 
7. Eaton L, Flisher AJ. HIV/AIDS knowledge amongst South African Youth. SA J Child Adolesc 














8. Woodhall SC, Lehtinen M, Verho T, Huhtala H, Hokkanen M, Kosunen E. Anticipated 
acceptance of HPV vaccination at the baseline of implementation: a survey of parental and 
adolescent attitudes in Finland. J Adolesc 2007; 40:466-469. 
9. Hopenhayn C, Christian A, Jay Christian W, Schoenberg NE. Human papillomavirus vaccine: 
knowledge and attitudes in two Appalachian Kentucky counties. Cancer Causes Control 
2007;DOI 10.1007/s10552-007-9007-7.  
10. Jaspan HB, Berwick JR, Myer L, Mathews C, Flisher AJ, Wood R, Bekker LG. Adolescent HIV 
prevalence, Sexual Risk, and Willingness to participate in HIV vaccine trials. J Adolesc 
2006;39:642-48. 
11. Villarruel AM, Jemmott LS, Jemmott JB, Eakin BL. Recruitment and retention of Latino 
Adolescents to a research study: lessons learned from a randomised clinical trial. J Spec 
Pediatr Nurs 2006;11(4):244-50. 
12. Mathews C, Guttmacher SJ, Flisher AJ, Mtshizana Y, Hani A, Zwarenstein M. Written parental 















Table 1: A comparison of responses to knowledge based questions with respect to TB vaccine 
trials and procedures by socio-economic group 









RR 95% CI 
TB      
TB is a kind of infection affecting mainly the 
lungs 
190 (70%) 102 (81%) 88 (61%) 1.32 1.13-1.55 
TB is spread by germs that have been coughed 
into the air 
211 (78%) 90 (71%) 121 (84%) 0.85 0.75-0.97 
With treatment TB can be cured 207 (77%) 95 (75%) 112 (78%) 0.97 0.85-1.11 
The direct cause of TB is a germ 144 (53%) 85 (68%) 59 (41%) 1.65 1.31-2.07 
Vaccines      
Vaccines are given to prevent infections 110 (41%) 72 (57%) 38 (26%) 2.14 1.56-2.92 
Vaccines are made of bits of dangerous germs 
that have been made safe 
68 (25%) 40 (32%) 28 (19%) 1.63 1.07-2.48 
Smallpox no longer occurs in the world due to a 
worldwide vaccination programme 














Research      
Research is when scientists try to find out 
something new 
199 (74%) 105 (83%) 94 (65%) 1.28 1.11-1.47 
 
*Group A, the schools from a higher socio-economic status comprised one grade 8, two grade 9, 
one grade 10 and one grade 11 class and group B, the lower socio-economic status schools 















Table 2 A comparison of responses to attitude based questions with respect to TB vaccine trials 
and procedures by socio-economic group 






RR 95% CI 
I would be willing to participate in research to 
answer questions 
85 (68%) 76 (53%) 1.28 1.05-1.56 
I would be willing to participate in research to be 
examined 
51 (41%) 65 (45%) 0.90 0.68-1.18 
I would be willing to participate in research to 
have skin tests 
45 (36%) 42 (29%) 1.22 0.87-1.73 
I would be willing to participate in research to 
have blood taken 
49 (39%) 57 (40%) 0.98 0.73-1.73 
Yes, I do want to know if I have HIV or not 50 (40%) 85 (59%) 0.67 0.52-0.87 
I would be more willing to take part in research 
if I personally got something in return 















Table 3 A comparison of knowledge of TB, vaccines and research versus willingness to undergo different procedures 
  Willingness to  
  Answer questions Be examined Have a skin test Have blood drawn 
  RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Knowledgeable about TB 1.42 1.13-1.8 1.27 0.93-1.72 2.04 1.31-3.18 1.21 0.87-1.67 
Knowledgeable about vaccines 1.41 1.16-1.71 1.39 1.06-1.82 1.56 1.1-2.2 1.29 0.96-1.73 















Figure 1:  
 
















a)      To answer 
questions 
b)      To be 
examined 
c)      To have skin 
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d)      To have blood 
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Chapter 8: Discussion and Conclusion 
This thesis set out to measure tuberculosis (TB) infection and disease prevalence and incidence, willingness to 
participate in TB vaccine trials and factors influencing these outcomes amongst school-going adolescents aged 12-18 
years in a high TB burden rural setting. The following was found: 
The prevalence of latent TB infection was 55% on the basis of the tuberculin skin test (TST) and 51% using the 
QuantiFERON TB Gold (in-tube) (QFT) assay. The main risk factors for latent infection on multivariate analysis were being 
of black/mixed race racial group compared to being white or Indian, male sex, older age, having had a household TB 
contact, low income and low education level. 
 
The prevalence of TB disease was 3/1000 (95% CI 1-4/1000). A positive TST (sensitivity 85% [95% CI 62-100%]) and QFT 
(sensitivity 94% [95% CI 79-100%]) were sensitive indicators of TB disease. In contrast, TB related symptoms (12.5% [95% 
CI 0.0-30.2%]) and household TB contact (31.3% [95% CI 0.0-63.9%]) were not. However, all these screening tests alone 
or in combination had positive predictive values of less than 2%. 
 
The incidence of bacteriologically confirmed TB was 0.45/100 person-years (95% CI 0.29-0.72) using a protocol defined 
case definition. When the case definition was varied, rates ranging from 0.30 to 0.59/100 person-years were obtained. 
The clinical profile of TB cases was mainly of the adult type and most had radiographic abnormalities on chest x-ray. 
Black or mixed race versus white/ Indian, maternal education of primary school or less or unknown, a positive baseline 
QFT and a positive baseline TST were significant predictors of TB disease in adjusted analysis. 
 
Both a positive TST and a positive QFT were equally predictive of the onset of TB on follow up at 0.60 cases per 100 person 
years (pyrs) (95% CI 0.43–0.82) and 0.64 cases per 100 pyrs (95% CI 0.45–0.87) respectively; incidence rate ratio [IRR] of TST to QFT 
was 0.95 (95% CI 0.59-1.51). 
 
Adolescents had fair knowledge about TB and were willing to participate in clinical trials of new TB vaccines but the 
















These results and their limitations were discussed in detail in the individual chapters and will not be repeated to any 
great extent here. Instead, specific discussion areas will be addressed. 
 
Feasibility of doing trials in adolescents 
The discussion below draws on different chapters of this thesis so as to address one of the underlying themes, viz 
feasibility of TB vaccine trials in adolescents. 
Adolescents as a target for TB vaccines 
There has been an important shift in approach in the TB vaccine world as outlined in the recently published Blueprint for 
TB vaccines (1, 2). Previously, the focus of TB vaccine development has been on infants, HIV positive persons and 
adolescents.  There has been a shift towards focusing efficacy trials of new TB vaccines on HIV negative adults and 
adolescents, at least initially, for the following reasons: 1) clinical endpoints are difficult to define in infants (3) and an 
infant vaccine will have limited immediate impact on the TB epidemic (4),  2) immune impairment in HIV positive 
persons may  limit TB vaccine efficacy, and 3) HIV negative adults and adolescents are the main source of disease 
transmission (5). Once efficacy has been established in adults and adolescents, efficacy trials or bridging trials will be 
done in infants and HIV positive persons. Although TB incidence rates are lower in adolescents than adults (6), it is still 
proposed to include them in these initial trials. A recent paper discussing a model Phase III TB vaccine efficacy trial 
proposes HIV negative adults and adolescents as a target group but provides an alternative option of focusing initially on 
adults with bridging studies to adolescents to follow (7). This latter option was based on concerns raised by the 
Medicines Control Council of South Africa about trials being conducted in adolescents (the Council views adolescents as 
a vulnerable group) and also on the lower rates of TB in adolescents than in adults. Nevertheless, adolescents were still 
seen as an attractive target due to their being accessible through schools for mass TB vaccine campaigns should these be 















Implications of the prevalence of latent TB infection in adolescents for TB vaccines 
The fact that there was a prevalence of latent TB infection in this adolescent population of just over 50% has 
implications for the type of vaccine to be tested in this group. Certain vaccines target those who are TB uninfected while 
others focus on those who are infected and some target both (8, 9). The data in this thesis show that substantial 
numbers of both groups are available for recruitment. However, TB incidence rates differ between the two groups and 
this would mean that much larger numbers would be needed to evaluate efficacy in latent TB negative adolescents. The 
identified risk factors may assist with targeting recruitment should one or other group be preferentially required to be 
enrolled.  Poorer communities, those that have had household contacts, age above 15 years or males may be 
preferentially enrolled should latently infected persons be required for recruitment and the opposite (those without 
household TB contacts, age 15 years or less or females) should latent infection negative persons be required. However, 
the ethics of such preferential selections would need to be carefully considered as well as the implications for eventual 
licensure should the vaccine prove efficacious.  Also, screening for latent TB infection prior to vaccination may not be 
practical with an approved vaccine suggesting that using latent TB infection as an inclusion or exclusion criterion in a 
licensure trial may bring challenges when the vaccine is available for public use. 
Screening for TB amongst adolescents in TB vaccine trials 
Exclusion of participants with TB disease would be necessary in all TB vaccine trials at baseline. The thesis data show a 
relatively low prevalence of TB disease in adolescents of 3/1000. This is good news for recruitment potential. However, 
the detection methods used underestimat d the prevalence because smear negative culture positive TB was not 
screened for. Nevertheless, prevalence would still be relatively low even if this group were included. While tests for 
latent infection were sensitive indicators of TB disease, the low positive predictive values mean that screening for TB, 
which is necessary in TB vaccine trials, will be costly and have a low yield. Other studies have shown chest radiography 
to be more sensitive at detecting TB (10, 11) and this may be an area for further investigation taking due cognizance of 
the practicality of using this method of screening in the efficacy trial context. A licensed TB vaccine, should this become 
a reality, would also require the exclusion of TB prior to administration but in depth screening may not be practicable. 
Only simple symptom screening with its limitations may be feasible. Thus, vaccine safety testing in persons with active 















Implications of the incidence rate of TB in adolescents for planning TB vaccine trials 
The incidence rate of TB in adolescents of 0.45/100 person years and the implications for the sample size of a phase IIb 
efficacy trial was discussed in chapter 5 (confidence interval for efficacy above 0).  There is no agreement as yet on the 
target efficacy for a new TB vaccine (2). However, there is a view that efficacy targets at this stage should be modest. A 
sixty percent reduction in disease between the vaccine and placebo groups appears to be a commonly used efficacy 
target based on current efficacy trials with MVA 85A in infants (12) and HIV positive adults (ClinicalTrials.gov identifier: 
NCT01151189) and from that which was used in a modelling exercise (4).  Using this efficacy target and accepting a 
lower confidence interval bound for an efficacy of 30%, the sample size for a Phase III trial in adolescents would be 
approximately 20,000 to 25,000 if one applies the data from this thesis and depending on assumptions made about loss 
to follow up.  Even higher sample sizes would be needed in other countries which are likely to have a lower TB incidence 
rate in adolescents. This will be too large a sample for enrolment at one site but phase III trials of such a magnitude 
would usually be multi-centred and thus feasible from that perspective. Given the geographical diversity of efficacy 
measures  for BCG (13), a multi-centred approach to trials of new TB vaccines would in fact be desirable.  As indicated 
above, the risk factors for TB disease show that measures of latent TB infection will have a strong influence on sample 
sizes.  The adult type profile of TB seen in adolescents will make endpoint definition easier than in infants and make 
efficacy results of trials in adolescents easier to interpret given that a specific case definition could be applied. 
Willingness to participate by adolescents in TB vaccine trials 
Adolescents and their parents in a high burden setting expressed a desire to participate in TB vaccine trials. While only 
40% said they would be willing to undergo phlebotomy and even fewer a skin test (32%), we managed to recruit 58% in 
the cohort study.  This shows that with correct marketing, adolescents may be persuaded to participate even when 
there are fears about procedures such as phlebotomy. Nevertheless, fear of blood draws appeared to be a common 

















In summary, based on the prevalence and incidence of TB in adolescents and the risk factors for these that were found 
in the studies reported in this thesis, and on the fact that adolescents remain an important target for TB vaccine trials, 
adolescent trials or trials including adolescents are feasible.   
 
Implications for TB control 
Another broad aim of this thesis was to examine the implications of TB epidemiology amongst adolescents for TB 
Control Programmes. This thesis has presented the prevalence and incidence of TB amongst adolescents in schools. 
The role of age and gender 
 There is an increasing incidence of TB in adolescence after the phase of low incidence in the pre-adolescent childhood 
years as shown by other studies (14, 15) and by this thesis. There has been speculation that this is due to hormonal 
changes and/or viruses but this has not been established (16, 17). The initial predominance of TB in females in 
adolescence followed by a male predominance in adulthood (14, 15) also point towards a hormonal explanation. The 
influence of psychosocial factors has been examined, but little evidence has been found to support these as an 
explanation of the increasing incidence (18).  Recent work in Cape Town is enlightening in that it confirms adolescence 
to be a period of high social interactions (19). In the context of communities with a high TB burden, this would mean an 
increased risk of exposure to active TB cases. The research group conducting the work on social interactions amongst 
adolescents also showed adolescence to be a period of high force of infection thereby supporting this hypothesis (14).  
Adolescents at schools represent a high proportion of all adolescents (83% in the thesis based study area according to 
Census 2001). Of note is that the distribution of TB amongst different schools was not uniform, with schools in poorer 
communities having a higher burden than those in more affluent communities. The role of HIV in the increasing TB 
incidence during adolescence is not clear since HIV prevalence tends to be lower amongst adolescents (20). It may not 
be the key driver in the age related rise in TB incidence but may accelerate the increase in the older age groups. 
Adolescents as an accessible group for intervention 
Given the high volumes of TB suspects being processed in current TB Control programme conditions, the number of 















(contact tracing, active case finding, TB education) in adolescence and to make adolescent TB a focus of interest. 
Nevertheless, a case can be made for giving this group attention. Adolescents represent an accessible group for 
screening and health promotion programmes through the schools.  The TB exposures in adolescence may in fact be 
responsible for the peak seen in adulthood. Thus, interventions in schools may be important for TB Control Programmes. 
A booster vaccination for diphtheria and tetanus is currently scheduled for adolescents aged 12 years in the routine EPI 
programme.  HPV vaccine is a vaccine being considered for administration in early adolescence.  New HIV and TB 
vaccines (should these be discovered in the future) could be added to the above in the adolescent period. Thus, there 
may be scope for greater involvement by the public health system in schools in the future which may then provide a 
framework and infrastructure within which TB control could be exercised. Clearly, primary prevention with an 
efficacious vaccine would be the best intervention but this does not currently exist. In the absence of such a vaccine, 
secondary prevention through contact screening may be a suitable alternative intervention particularly when 
adolescents are diagnosed while at school.  Contact tracing usually focuses on household contacts and including 
screening of school class contacts for adolescents may be needed.  
The challenges of screening for TB 
The fact that symptoms were not reported in most cases diagnosed at baseline is cause for concern. This may be due to 
early detection of disease, a reluctance by adolescents to report symptoms or due to adolescents not recognising cough 
as a symptom due to smoking. Active untreated cases in the school environment where adolescents congregate in 
classrooms may be the cause of the high force of infection found in adolescents (21). The lack of symptoms complicates 
screening efforts since carrying out TSTs or drawing blood for QFT may not be feasible or cost-effective. Thus, routine 
screening is not likely to be feasible in the current environment. However, since TB incidence has an uneven distribution, 
with higher rates in poorer communities, some targeting of interventions may be needed.   
Education interventions 
The data in this thesis (chapter 7) showed that knowledge of TB was fair amongst adolescents. Improving adolescent 
knowledge of TB may be of value in improving early detection of TB as a means of limiting the spread of TB. Knowledge 
of vaccines was poor. This should be improved so that acceptability of a new TB vaccine is high should one become 
















Sputum GeneXpert screening of TB suspects may be worthwhile exploring given its higher sensitivity than normal 
sputum smears and its rapid turnaround of results, with rifampicin resistance screening as an additional benefit (22). 
This diagnostic test was not evaluated in the work contributing to this thesis but is currently being rolled out in the 
public health system of South Africa (23). It may more correctly be described as a diagnostic tool rather than a screening 
tool since a positive result is enough to initiate treatment without the need for further investigations.  There may be 
implementation obstacles in trying to use it as a screening tool since it requires the provision of an adequate sputum 
sample. It could be used as part of a screening algorithm where only symptomatic individuals who have a productive 
cough are tested. 
 
In summary, a case can be made for targeting adolescents at school for interventions to support TB control efforts. Re-
establishing contact tracing using GeneXpert as a screening tool with an emphasis on poorer communities, in 
combination with health education may be the most feasible option currently given the absence of an efficacious 
booster TB vaccine.  
Isoniazid prophylaxis 
A repeated concern raised by international reviewers of the published work from this thesis was the lack of isoniazid 
preventive therapy (IPT) for adolescents confirmed to be latently infected with M. tuberculosis. Firstly, they argued that 
a higher standard of care might be expected in a research environment since more resources may be available through 
international funding. Secondly, prior trials have shown that IPT is beneficial in reducing the risk of progression to TB 
(24) and it is thus standard of care in many countries. Thirdly, the data from this thesis showed a three times higher risk 
of progression to TB when latently infected (chapters 5 and 6).  The current standard of care in South Africa is that IPT is 
only provided to children under the age of 5 years exposed to an infectious adult with TB disease and to HIV positive 
persons shown not to have evidence of active TB disease (25, 26). The Human Research Ethics Committee of the 
















Prior trials of IPT done in the 1950s and 60s were done in both developed and developing countries (24).  These studies 
were done in the in pre HIV era and thus represent data for efficacy in the HIV negative population. These studies 
showed a protective efficacy of isoniazid therapy of 90% when the analysis was done only on compliant participants. 
Importantly, the benefit of IPT in preventing TB was shown to last up to 19 years after administration (27). These 
findings with respect to INH prophylaxis in HIV negative populations were confirmed by a more recent Cochrane review 
published in 2005 which included 11 studies from developed and developing countries (28).  In this review, only studies 
with a minimum 2 year follow up were included and they found a relative risk of 0.4 (95% CI 0.31-0.52) of contracting TB 
if on isoniazid prophylaxis for 6 or 12 months.  They also found the risk of death from TB was significantly reduced when 
on prophylaxis. 
 
Contrasting results have been found in other trials. A recent trial amongst South African gold miners (HIV positive and 
negative) investigated the value of IPT as an intervention strategy (29, 30). Miners on IPT had a reduced risk of 
developing TB disease but once they had stopped the course of treatment, their risk of TB was not different from those 
not on IPT. The IPT trial in Botswana evaluating 36 months of isoniazid treatment in HIV positive adults similarly showed 
benefit while trial participants were on IPT (particularly for those that were TST positive at baseline) but this benefit was 
also lost once treatment had been stopped (31). The high risk of reinfection may be responsible for this lack of long term 
benefit in these studies (32). Thus, the long term benefit of IPT when given for a limited duration of time is not as clear 
cut in a high burden setting as in a low risk setting and studies on lifelong IPT have not yet been  done.  Recent World 
Health Organisation and South African guidelines on IPT for HIV positive persons both clearly recommend IPT for HIV 
positive persons (26, 33). The CDC (Atlanta, USA) currently recommend IPT for latent TB infection more broadly than HIV 
positive persons and children under 5 years but their most recent guidelines only focus on testing high risk groups for 
latent TB infection (34). These high risk groups include HIV positive persons, persons on immunosuppressive therapy, 
recent immigrants who have been in the country for less than 5 years, children under 5 years, workers in high risk 
occupations and persons with illnesses which predispose to contracting TB. In other words, current practice in the USA is 
















The prevalence of latent TB infection is high (>50%) in South African adults and adolescents in the high burden area 
where the studies for this thesis were conducted.  There would be enormous resource considerations should IPT be 
implemented for HIV negative persons.  Adverse events due to the medication would be a concern since hepatitis (28) 
and peripheral neuropathy can occur with isoniazid administration.  While these side effects are uncommon, there 
should be a clear benefit to justify the exposure to these risks. Given the inconsistent benefits and potential harm, it is 
difficult to justify its use as routine for all persons who are infected. Nevertheless, the high burden of TB in South Africa 
requires us to explore all avenues to bring TB under control. It may be worthwhile exploring IPT in an adolescent setting 
given the limited number of studies of IPT in high burden settings amongst HIV negative populations. Responses may be 
different from gold miners who have been exposed to silica dust, a known risk factor for TB. 
 
The nature of latent TB infection has come under scrutiny (35, 36). There is now a common view that latent TB infection 
represents a continuum of states rather than a single entity and that despite the absence of symptoms, host-organism 
interaction is occurring at a local level. The presence of Mycobacterium tuberculosis (Mtb) in tissues of individuals not 
diagnosed with TB is still being demonstrated in the modern era (37). Further investigation and insight may be needed 
to understand the nature of latent infection before implementing interventions such as IPT. 
 
In summary, there is currently not enough evidence to support IPT in adolescents in high burden settings but further 
discussion and research on this issue are needed. 
The IGRA debate: IGRA versus TST  
Data from this thesis were used to support US policy development on IGRAs (38). A review and meta-analysis done in 
children has shown that IGRAs appear to behave differently in high burden compared to low burden settings (39). A key 
issue has been the predictive value of TST versus IGRA for TB disease. One recently published systematic review and 
meta-analysis found that both IGRAs and TST were both poor predictors of TB disease (based on positive predictive 
values) and that other factors such as costs, relative specificity in different populations, etc.,  should guide which to use 















of the TST and recommended their use over the TST, particularly when targeted at high risk groups (41).  Data from this 
thesis were quoted in both reviews.  The first review included 15 studies in its meta-analysis but then focused its main 
analysis on 5 studies because of concerns that the data from certain studies were subject to incorporation bias or 
differential work-up bias and the data in this thesis was classified as such. This was a valid concern in that a positive IGRA 
was an indication for investigation for TB in the study reported in this thesis. However, this author’s view is that the 
impact of this potential bias was limited since there were other criteria for investigation such as symptoms, household 
contact and a positive TST and in addition, surveillance of clinics was conducted for any cases diagnosed by the health 
services. The authors of the first review (40) found a predictive value based on the restricted group of 5 studies of 2.11 
(95% CI 1.29-3.46) for IGRAs versus 1.60 (0.94 – 2.72) for the TST using the 10 mm cut-off.  
 
The second meta-analysis included 28 studies since it was published later and more data had become available. They did 
a subset analysis on a group of studies which recruited high risk populations. They reported a predictive value for TB 
disease of 2.7% (95% CI 2.3-3.2%) for the IGRA compared to 1.5% (95% CI 1.2-1.7%) for the TST when all 28 studies were 
included. When only the high risk group was analysed, the PPV was 6.8% (95% CI 5.6-8.3%) for IGRA and 2.4% (95% CI 
1.9-2.9%) for TST. They excluded the study published from this thesis from their “high risk” group since they argued that 
only 25% of participants had reported a household contact, a high proportion were positive for TST and the IGRA 
amongst those with a recent contact, and because there was no difference in TB incidence rates between those recently 
exposed compared to those more remotely exposed in time.  Clearly, these authors misunderstood that absence of 
evidence of contact in high burden settings does not define these settings as low risk. A higher proportion positive for 
latent TB infection in those recently exposed could be due to waning of responses over time or could confirm that 
exposures are more recent. The data comparing incidence rates amongst those recently exposed to those remotely 
exposed shows a clear trend of higher incidence amongst those more recently exposed – the lack of significance was 
more likely to be due to a lack of power rather than a lack of a difference. Their reasons for excluding this thesis’s study 
from the high risk group do not appear to be valid. The authors of this second review did not address the question of 
heterogeneity which was reported as high but not discussed as a limitation. They used cumulative incidence rather than 
















Currently, guidelines on IGRAs in various countries around the world have adopted varying approaches (42). The WHO 
which also used the data reported in this thesis has produced a policy document on the use of IGRAs in low and middle 
income countries and has concluded that both IGRAs and the TST cannot accurately predict the onset of TB and neither 
should be used for the diagnosis of TB disease (43). Most individuals (>95%) with a positive IGRA test do not develop TB. 
In addition, because of cost and complexity, IGRAs are not recommended for use in low and middle income countries. 
South Africa does not have a policy on the use of IGRAs although IGRAs are available in the private sector. While the 
WHO policy document provides a useful guide for the use of IGRAs, the data in this thesis and those from other studies 
done in South Africa and elsewhere on the African continent should be able to provide the basis to support policy 
formulation on IGRAs in the region. 
 
In summary, the use of IGRAs remains controversial and its value in high burden settings remains moot. South Africa and 
other high burden countries should develop guidelines on the use of IGRAs given the inconsistent findings in the 
literature. In line with the recommendations of the WHO, this author would recommend a cautious attitude towards 
introducing IGRAs in high burden settings for routine use. However, given the lack of data on their performance in high 
burden settings, their use and evaluation in research projects should be allowed and encouraged so that there is a 
comprehensive basis for policies on their use in high burden settings in the future. 
Further areas of research 
Not all the data produced from the studies that formed the basis for this thesis are included in this thesis and further 
publications are planned. These include a study of the role of QFT quantitative values in predicting TB disease, a 
comparison of surveillance methods for detecting TB disease and an analysis of conversions and reversions of both the 
TST and QFT. 
 















 Chest radiography as a screening tool for TB in adolescents. This could be studied in two ways:  Purchasing a 
mobile x-ray unit for research purposes and screening all participants. Alternatively, using an investigation 
algorithm where selected participants are screened with a chest x-ray which is then performed by locally 
available services. 
 Cost-effectiveness of different screening tests for TB in adolescence. Costs of the different screening methods 
would be collected and then evaluated against screening indicators such as sensitivity, specificity, positive and 
negative predictive values. 
 The yield of GeneXpert as a screening tool to screen adolescents at school for TB disease. A cross-sectional study 
of adolescents in a school setting could be performed in which either universal or selective GeneXpert screening 
is done. 
 The potential benefit of IPT in adolescents in a high burden setting. This would involve a randomised controlled 
trial in which adolescents who are randomly assigned to either IPT (at least 6 months) or placebo and followed 
up. It would be important to include at least two years of post-treatment follow up since it would be crucial to 


















The data in this thesis have made a contribution to the literature on adolescent TB. The incidence and prevalence of TB 
infection and disease data, and the willingness to participate in clinical trials data should be of great value in planning 
clinical trials of new TB vaccines. This thesis has provided information for TB Control Programmes to support possible TB 
control interventions in adolescents. The IGRA data should contribute to the debate on the use of this technique in high 
burden settings, especially since the studies reported in this thesis are amongst the largest comparing the TST with an 
IGRA. The use of IPT in HIV negative persons remains a vexing question and there are still gaps in the literature with 
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Overall methodology of adolescent cohort study (to be read in conjunction with Appendix B which provides a graphic 
illustration of study design) 
Study setting: The study took place in the town of Worcester (and surrounding villages), approximately 100 kilometres 
from Cape Town, South Africa.   
Study participants: All adolescents aged 12-18 years attending 11 high schools in the study area were approached to 
participate. 
Study procedures: At enrolment, a questionnaire was administered to study participants and their parents to collect 
demographic and socio-economic data. These included parental income and parental education. The racial classification 
of participants “White”, “Mixed race”, “Indian” and “Black” was based on a system used in the apartheid era, but still 
used today as a proxy for socio-economic status and to measure social change.  History of BCG vaccination (reported), 
history of current and past TB disease, current and past TB household contacts, hospitalization in the past 6 months and 
information on chronic diseases were obtained. Participants were examined for the presence of a BCG scar. 
 
Blood was taken for QuantiFERON® TB Gold In-tube (Cellestis). A tuberculin skin test was then immediately administered 
using the Mantoux method on either forearm, using 2 tuberculin units of RT23 (Statens Serum Institut, Denmark).  
Induration at the TST site was read 48 - 96 hours later with a ruler or a caliper, by trained study personnel. Those with 
previous or current TB did not have a TST performed, in order to prevent severe allergic reactions. The QuantiFERON 
test (QFT) was performed as recommended by the manufacturers. 
 
The first 481 participants enrolled were all screened with a single sputum culture. For logistical reasons (the 















was then amended to only screen the following: those with (1) TB symptoms (unexplained cough, night sweats, loss of 
weight or loss of appetite for two weeks or more, or haemoptysis), (2) a household contact within three years of 
enrolment, (3) a TST >10mm, or (4) a positive QFT. These participants were considered TB suspects and were 
investigated by the collection of two sputum samples for smears on two separate occasions. The sputum was 
concentrated and examined with a fluorescent stain (auramine). A positive smear was followed by a culture (liquid, 
Mycobacteria Growth Indicator Tube (MGIT) and solid, Loewenstein-Jensen) to confirm the presence of Mycobacterium 
tuberculosis, a chest radiograph and an HIV test.  
Study follow up: All participants enrolled were scheduled for follow up visits after two years which included a blood draw 
for QFT and the administration of a TST. About half underwent three monthly visits prior to this which included six 
monthly QFTs and annual TSTs to compare follow up strategies while the other half were seen only at baseline and two 
year. At follow up visits, those with new symptoms or a new household contact compared to baseline, a converted TST 
(>10 mm increase from baseline) or converted QFT (change from negative to positive) were investigated for active TB. In 
addition, passive surveillance was conducted of TB clinic and hospital admission registers in the area for any TB cases 
diagnosed between visits.  Investigation for TB involved the collection of two sputum samples for smear examination on 
two separate occasions. For persons with at least one positive smear, a culture was performed, a chest x-ray done and 
an HIV test offered. The radiologist’s report on the chest –x ray was used to classify chest-x-ray findings.  
Study duration: Enrolment started in July 2005 and was completed in April 2007. Follow up was completed at the end of 
February 2009. Owing to financial constraints, about 10% of the two year visits were performed one to two months 
short of two years towards the end of the study. Follow up was thus continued for a minimum of 22 months. Those 
completing their two year visits were followed up passively until all other subjects had completed their two year visits. 
This gave a maximum follow up time of 3.8 years.   
Definitions: 
The protocol definition of a TB case was a diagnosis of intrathoracic tuberculosis with either two positive sputum smears 















TB treatment by a physician were recorded (“all TB”). A chest x-ray consistent with active tuberculosis was defined as 
“compatible with TB” - this included pleural effusions. An “abnormal chest x-ray” was defined as any abnormality judged 





















































 Questionnaire used in Knowledge and Attitudes study (Chapter 7) 
 
South African TB Vaccine Initiative (SATVI) 
University of Cape Town 
 
Knowledge and attitudes questionnaire for school-going pupils in the Worcester, De Doorns 
and Rawsonville areas. 
This questionnaire will not be used for exam purposes. 
 
Instructions: 
1. Do not put your name on this paper. It is an anonymous survey. 
2. Circle the answers which you think are correct or which reflects your point of view.   
3. Circle “Don’t know/ Not sure” if do not know what answers are correct or if you are not sure.  
4. For each question, you may circle as many answers as you wish. 
5. Read through all the options before you make your choice. 
------------------------------------------------------------------------------------------------------------ 
1 TB is a: 
a) Kind of cancer affecting the lungs 
b) Kind of infection affecting mainly the lungs. 
c) Heart problem 
d) Kind of asthma 
e) Don’t know/ Not sure 
 
2 The direct cause of  TB is : 
a) Smoking 
b) Stormy weather 
c) A germ 
d) Exercise 
e) Don’t know/ Not sure 
 




d) All of the above 
e) None of the above 
















4 TB is mainly spread by: 
a) Blood 
b) Touching 
c) Germs which have been coughed into the air 
d) Sexual intercourse 
e) Don’t know/ Not sure 
 
5 With treatment, TB can be fully cured: 
a) True 
b) False 
c) Don’t know/ Not sure 
6 HIV is a: 
a) Kind of cancer 
b) Kind of Infection 
c) Heart problem 
d) Kind of asthma 
e) Don’t know/ Not sure 
 
7 The direct cause of  HIV/AIDS is : 
a) Smoking 
b) Poverty 
c) A virus 
d) Sexual intercourse 
e) Don’t know/ Not sure 
 
8 The chances of getting HIV is higher when: 
a) Someone has many sexual partners 
b) There is over-crowding 
c) Someone smokes 
d) All of the above 
e) None of the above 
f) Don’t know/ Not sure 
 
9 HIV is mainly spread by: 




e) Blood transfusions 
f) Don’t know/ Not sure 
 

















c) I am not at risk of HIV 
d) Don’t know/ Not sure 
e) Maybe 
f) I don’t want to answer this question 
g) I know already (I have had an HIV test) 
 
11 A vaccine or immunisation is given : 
a) To give energy 
b) To help growth in a child 
c) When a child is sick 
d) To prevent the development of infections 
e) Don’t know/ Not sure 
 
12 A vaccine or immunisation is made of: 
a) Chemicals 
b) Vitamins 
c) Bits of dangerous germs which have been made safe 
d) Animal bits. 
e) Don’t know/ Not sure 
 
13 The disease small pox no longer exists in the world because: 
a) The germ died out naturally 
b) People around the world were vaccinated against small pox 
c) Chemicals were used to kill off the small pox germ around the world. 
d) The small pox virus changed into something harmless. 
e) Don’t know/ Not sure 
 
14 Vaccines are given 
a) Mainly to children 
b) By doctors and nurses 
c) Free of charge 
d) All of the above 
e) None of the above 
f) Don’t know/ Not sure 
 
15 Research is 
a) When scientists try to find out something new. 
b) When an experiment is conducted on people without their permission. 
c) Only used to develop new weapons 
d) Only about reading books. 
e) Don’t know/ Not sure 
 
16 Would you be willing to participate in research (you may circle more than one option): 
a) To answer questions 
b) To be examined 















d) To have blood taken 
e) Don’t know/ Not sure 
 
17 Would you be more willing to take part in research (you may circle more than one option): 
a) If you got more information 
b) If the community benefited 
c) If the school got something in return 
d) If you personally got something in return 
e) If someone you know monitored the research 
 




d) Brothers/ Sisters 
e) Other such as_____________________________________________ 
 




d) Radio/ TV 
e) Friends 
f) Magazines 
g) Your private doctor 
h) Clinics or hospitals 
i) Other, please specify________________________________________ 
 
 
Thank you for your assistance 
 
